An Evidence-Based Overview of Eurycoma longifolia (Tongkat Ali): Effects on Testosterone Levels and Prostate Health - Integrative Functional Medicine Edited by Yoon Hang Kim, MD, MPH Dr. Yoon Hang “John” Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL—where he provided care to rural and underserved populations—Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible regardless of location. His clinical approach integrates functional medicine laboratory testing with complementary therapies, including meditation, yoga, tai chi, and lifestyle interventions that use food and physical activity as medicine to address root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a Master of Public Health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Board-certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, Dr. Kim has served as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. His clinical interests include autoimmune disease, chronic pain, integrative oncology, and gastrointestinal disorders. He specializes in complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID, and toxic mold illness. Dr. Kim has authored two books and more than 20 peer-reviewed and professional articles and has helped establish integrative medicine programs across multiple institutions. Professional Inquiries: www.yoonhangkim.com Clinical Inquiries: www.directintegrativecare.com Introduction to Eurycoma longifolia Eurycoma longifolia Jack, commonly known as Tongkat Ali or Longjack, is a traditional Southeast Asian medicinal herb derived from the roots of a shrub native to Malaysia and Indonesia. It has gained increasing scientific interest for its potential to enhance male vitality, primarily through modulation of testosterone levels. This article reviews the current evidence regarding Eurycoma longifolia’s effects on serum testosterone and prostate health, drawing from randomized controlled trials (RCTs), systematic reviews and meta-analyses, and preclinical studies. Clinical Evidence on Testosterone Enhancement A growing body of clinical research supports the ability of Eurycoma longifolia supplementation to increase serum testosterone, particularly in men with hypogonadism or age-related androgen decline. However, interpretation of this evidence requires attention to methodological limitations. Systematic Review and Meta-Analysis Evidence A 2022 systematic review and meta-analysis by Leisegang et al. evaluated nine studies, five of which were included in the quantitative meta-analysis. The pooled analysis demonstrated a statistically significant increase in total testosterone, with a standardized mean difference (SMD) of 1.352 (95% CI: 0.565–2.138; p = 0.001). The effect was most pronounced in hypogonadal men, though benefits were also observed in eugonadal individuals. Subgroup analysis revealed greater improvements among participants with low baseline testosterone levels. Methodological Considerations Several important limitations must be acknowledged: Publication bias: Begg’s test indicated significant publication bias (p = 0.0243), with additional bias detected in the hypogonadal subgroup using Egger’s and Begg’s tests, suggesting overrepresentation of positive findings. Industry involvement: Seven of the nine studies utilized Physta®, a proprietary extract produced by Biotropics Malaysia Berhad. Several trials were industry-funded, and some authors were company employees. While not invalidating the results, this represents a potential conflict of interest. Heterogeneity: Substantial heterogeneity was observed across studies (I² = 87.27%), reflecting variability in study populations, dosing, duration, and outcome measures. Key Individual Clinical Trials Chinnappan et al. (2021): A multicenter, double-blind, placebo-controlled RCT involving 105 men aged 50–70 years with baseline testosterone <300 ng/dL found that daily supplementation with 100 mg or 200 mg of a standardized aqueous extract (Physta®) for 12 weeks significantly increased total testosterone. The 200 mg dose produced earlier and stronger effects, with significance observed as early as week 4. Quality-of-life scores also improved. This study was funded by Biotropics Malaysia Berhad, and two authors were company employees. Leitão et al. (2021): In a six-month RCT involving 45 men with androgen deficiency of aging males (ADAM), 200 mg/day of Eurycoma longifolia combined with concurrent training significantly improved erectile function and increased total testosterone. Approximately 50% of participants demonstrated testosterone increases, with the greatest benefits observed in the combined exercise and supplementation group. Chan et al. (2021): In a study of 32 healthy young men (mean age 24), supplementation with 600 mg/day for two weeks increased total testosterone by 15% and free testosterone by 34% compared with placebo. Luteinizing hormone and follicle-stimulating hormone levels did not change, suggesting a mechanism independent of direct hypothalamic-pituitary-gonadal axis stimulation. The hypothalamic-pituitary-adrenal axis has been proposed but remains speculative. Collectively, these studies suggest that doses of 200–600 mg/day of standardized extracts (typically containing 0.8–1.5% eurycomanone) administered for 2–12 weeks may increase testosterone levels, with potential benefits for energy, libido, and muscle strength. Individual response variability remains substantial. Clinical Evidence on Prostate Health Direct human clinical evidence evaluating Eurycoma longifolia’s effects on prostate health outcomes—such as benign prostatic hyperplasia (BPH), prostate volume, prostate-specific antigen (PSA), or prostate cancer risk—is limited. No large-scale RCTs have specifically assessed prostate-related endpoints. Preclinical Evidence Preclinical findings offer mixed insights. In vitro studies of quassinoids such as eurycomanone demonstrate anti-proliferative and pro-apoptotic effects in prostate cancer cell lines. Tong et al. (2015) reported that a standardized quassinoid composition (SQ40) inhibited LNCaP prostate cancer cell growth via G0/G1 cell cycle arrest, apoptosis induction, reduced androgen receptor translocation, and decreased PSA secretion. In mouse xenograft models, SQ40 significantly suppressed tumor growth. Animal models of testosterone-induced BPH have shown reduced prostate weight and improved histopathology with certain extracts. However, other rodent studies raise concerns that high doses may induce prostatic epithelial proliferation and dysplastic changes, potentially mediated by elevated testosterone levels. No human studies have reported increased PSA levels or prostate cancer incidence associated with Eurycoma longifolia use. Nonetheless, due to its androgen-enhancing effects, caution is generally advised in individuals with known prostate disease. Many clinical guidelines contraindicate its use in active prostate cancer. Safety and Tolerability Clinical trials report good tolerability at doses ranging from 100–600 mg/day, with no significant adverse effects on liver, kidney, or prostate markers over study durations of 2–24 weeks. Reported side effects have been mild and infrequent, including gastrointestinal discomfort and pruritus. Long-term safety data in humans remain limited. Medical supervision is recommended for individuals with hormonal sensitivities, prostate disorders, or those taking medications that may interact with androgenic compounds. Conclusion Eurycoma longifolia (Tongkat Ali): Effects on Testosterone Levels and Prostate Health - Integrative Functional Medicine Current evidence suggests that Eurycoma longifolia may be an effective natural agent for increasing testosterone levels, supported by multiple RCTs and a recent meta-analysis. However, the evidence base has important limitations, including significant publication bias, substantial industry involvement, high heterogeneity, and relatively small sample sizes. Its role in prostate health remains unclear. While preclinical data suggest potential anti-cancer activity, theoretical risks related to androgen elevation warrant caution. Well-designed, independently funded, long-term human studies are needed to clarify both efficacy and prostate-specific safety outcomes. Evidence Quality Assessment Strengths Multiple double-blind, placebo-controlled RCTs Statistically significant pooled effect in meta-analysis (SMD = 1.352) Consistent testosterone increases in hypogonadal and eugonadal men Favorable short-term safety profile Limitations Significant publication bias (p = 0.0243) Heavy reliance on a single proprietary extract High inter-study heterogeneity (I² = 87.27%) Limited long-term safety data Absence of large prostate-specific clinical trials At Direct Integrative Care, Dr. Kim provides personalized, patient-centered integrative medicine focused on identifying root causes and restoring balance. Through compassionate care and evidence-based therapies, patients are empowered with the knowledge and tools needed for sustainable health and vitality. Yoon Hang Kim, MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References References Chan, K. Q., Stewart, C., Chester, N., Hamzah, S. H., & Yusof, A. (2021). The effect of Eurycoma longifolia on the regulation of reproductive hormones in young males. Andrologia, 53 (4), e14001. https://doi.org/10.1111/and.14001 Chinnappan, S. M., George, A., Pandey, P., Narke, G., & Choudhary, Y. K. (2021). Effect of Eurycoma longifolia standardised aqueous root extract–Physta® on testosterone levels and quality of life in ageing male subjects: A randomised, double-blind, placebo-controlled multicentre study. Food & Nutrition Research, 65 , Article 5647. https://doi.org/10.29219/fnr.v65.5647 Leitão, A. E., Vieira, M. C. S., Pelegrini, A., da Silva, E. L., & Guimarães, A. C. A. (2021). A 6-month, double-blind, placebo-controlled, randomized trial to evaluate the effect of Eurycoma longifolia (Tongkat Ali) and concurrent training on erectile function and testosterone levels in androgen deficiency of aging males (ADAM). Maturitas, 145 , 78–85. https://doi.org/10.1016/j.maturitas.2020.12.002 Leisegang, K., Finelli, R., Sikka, S. C., & Panner Selvam, M. K. (2022). Eurycoma longifolia (Jack) improves serum total testosterone in men: A systematic review and meta-analysis of clinical trials. Medicina, 58 (8), Article 1047. https://doi.org/10.3390/medicina58081047 Tong, K. L., Chan, K. L., AbuBakar, S., Low, B. S., Ma, H. Q., & Wong, P. F. (2015). The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells. PLOS ONE, 10 (3), e0121752. https://doi.org/10.1371/journal.pone.0121752

Low Dose Naltrexone (LDN) for Lyme Disease: An Integrative Medicine Perspective Yoon Hang "John" Kim, MD, MPH Board-Certified Integrative Medicine Physician Direct Integrative Care Keywords: Low Dose Naltrexone, LDN, Lyme Disease, Post-Treatment Lyme Disease Syndrome, Integrative Medicine, Functional Medicine, Chronic Inflammation, Immunomodulation Low Dose Naltrexone (LDN) for Lyme Disease: About the Author Dr. Yoon Hang "John" Kim, residential fellowship trained in integrative medicine at University of Arizona and a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com Why I Started Using LDN for My Lyme Patients If you're reading this, chances are you or someone you love is struggling with Lyme disease—and you're searching for answers beyond the conventional playbook. I get it. After two decades of practicing integrative medicine and seeing thousands of patients with complex chronic illness, I've learned that Lyme rarely plays by the rules. Here's what frustrates me: Lyme disease is now the most common vector-borne illness in North America, yet so many patients feel abandoned by the healthcare system. They get their round of antibiotics, and when symptoms persist—the crushing fatigue, the brain fog, the joint pain that just won't quit—they're often told it's "all in their head." It's not. And that's exactly why I turned to LDN as part of my functional medicine approach. Low Dose Naltrexone, or LDN, has become one of my go-to tools for patients dealing with the aftermath of Lyme. It's not a magic bullet—nothing is—but for the right patient, it can be a game-changer. Let me walk you through what we know, what we're still learning, and how I use it in my integrative medicine practice. First, Let's Talk About What We're Really Dealing With Lyme disease starts simply enough: a tick bite, often unnoticed, delivers Borrelia burgdorferi bacteria into your system. If you're lucky, you spot that classic bull's-eye rash—the erythema migrans that practically screams "Lyme!" You get treated early, and you're fine. But here's the reality I see in my practice: many of my Lyme patients never saw a rash. Or they did see it, got antibiotics, and still ended up sick months later. Research from Johns Hopkins tells us that roughly 10-20% of properly treated Lyme patients develop what we call Post-Treatment Lyme Disease Syndrome, or PTLDS (1,2). That's a lot of people left suffering. These folks aren't making it up. They're dealing with real, measurable inflammation. Studies show elevated cytokines like IL-6, TNF-alpha, and IL-23 in PTLDS patients (5,6). Their immune systems are stuck in overdrive, and that's where functional medicine—and LDN—can really shine. So What Exactly is LDN? Here's where it gets interesting. Naltrexone has been around since the 1980s as a treatment for opioid and alcohol addiction—at doses of 50-100mg. But back in 1985, a brilliant physician named Dr. Bernard Bihari discovered something unexpected: at much lower doses (we're talking 0.1-4.5mg), naltrexone does something completely different. Instead of just blocking opioid receptors, it actually helps regulate the immune system (9). Think of it this way: when you take LDN at bedtime, it briefly blocks your opioid receptors for about 4-6 hours. Your body responds by ramping up production of endorphins—your natural feel-good, immune-regulating molecules. By morning, you've got more endorphins on board, and your immune system has gotten a gentle nudge toward balance (10). This is exactly the kind of approach we embrace in integrative medicine: working with your body's own healing mechanisms rather than against them. How LDN Actually Helps Lyme Patients When I explain LDN to my Lyme patients, I focus on four key mechanisms. Understanding these helps you appreciate why this humble medication can make such a difference. It Calms Down Overactive Immune Signaling One of the most exciting discoveries about LDN is its ability to quiet down something called Toll-Like Receptor 4, or TLR4. This receptor is like an alarm system on your immune cells—helpful when there's a real threat, but problematic when it won't stop ringing. In chronic Lyme, that alarm often stays stuck in the "on" position, pumping out inflammatory signals. LDN helps turn down the volume (11,12). It Addresses Brain Inflammation If you've got "Lyme brain"—that awful fog where you can't find words or remember why you walked into a room—this one's for you. LDN modulates microglial cells, the immune cells in your brain. It helps shift them from an angry, inflammatory state to a calmer, more supportive one (13,14). Many of my patients notice improved mental clarity within weeks of starting LDN. It Rebalances Your Immune System Chronic Lyme often throws the immune system out of whack—too much activity in some areas, not enough in others. In functional medicine terms, we see imbalances in Th1/Th2 responses and overactive Th17 pathways. LDN helps restore equilibrium, which is exactly what we're aiming for when we take an integrative medicine approach to complex illness (15). It Boosts Your Body's Natural Painkillers Remember that endorphin boost I mentioned? That translates to real-world pain relief for many patients. Unlike conventional pain medications that can create dependency and have significant side effects, LDN works by enhancing what your body already produces (16). What Does the Research Actually Show? I'll be honest with you—and this is important if you're doing your own research—we don't yet have randomized controlled trials specifically looking at LDN for Lyme disease. What we do have is compelling clinical experience and solid evidence from related conditions. Dr. Richard Horowitz, who's treated over 12,000 Lyme patients, shared his experience at the 2012 Integrative Healthcare Symposium. In his practice, about 75% of Lyme patients experienced meaningful improvement in fatigue, muscle pain, and joint discomfort when taking LDN (17). That's a remarkable response rate for a medication with such a favorable safety profile. We also have good data from fibromyalgia, which shares many features with chronic Lyme. A Stanford University trial found that LDN reduced pain by nearly 29% compared to 18% with placebo—and half the patients were rated as "much improved" or "very much improved" (18). A 2024 meta-analysis confirmed these findings across multiple trials (19). For me as a functional medicine practitioner, this evidence—combined with what I see every day in my practice—makes LDN a valuable tool in managing chronic Lyme. How I Use LDN in My Integrative Medicine Practice Choosing the Right Patients Not everyone with Lyme needs LDN, and it's not my first-line treatment for acute infection. Where LDN really shines is for patients who've completed appropriate antibiotic therapy but still feel lousy, folks struggling with persistent fatigue, brain fog, and widespread pain, patients with signs of immune dysregulation or autoimmune features, and those who want to reduce their reliance on conventional pain medications. Starting Low and Going Slow Since LDN isn't available commercially in low doses, you'll need a compounding pharmacy. I typically start patients at just 0.5-1mg at bedtime and increase by 0.5mg every week or two. Most people end up somewhere between 3-4.5mg. This gradual approach minimizes side effects and helps us find your sweet spot (21). If you experience vivid dreams or trouble sleeping—the most common early side effects—we can switch to morning dosing. These issues usually fade within a few weeks. The Bigger Picture: A Functional Medicine Approach Here's something I tell every Lyme patient: LDN is a tool, not a complete solution. True healing from chronic Lyme requires addressing the whole picture. In my integrative medicine practice, that means looking at your diet (anti-inflammatory eating is crucial), supporting detoxification pathways, addressing any co-infections, optimizing sleep, managing stress, and supporting mitochondrial function. Dr. Horowitz calls this the "16-point map" approach, and it resonates deeply with how we practice functional medicine. You can't just treat one piece of the puzzle and expect everything to fall into place (23). A Few Important Cautions I want to be straight with you about the limitations. We need more research—specifically, randomized trials in Lyme patients. While the evidence from clinical experience and related conditions is encouraging, it's not the same as having definitive proof. Also, not everyone responds to LDN. In my experience, about 60-75% of patients see meaningful benefit. For the others, we need to keep exploring different approaches. And critically: if you're currently taking opioid medications, you cannot start LDN without an appropriate washout period. LDN will precipitate withdrawal, which is dangerous and extremely unpleasant. Always work with a knowledgeable healthcare provider (22). The Bottom Line After twenty years of practicing integrative medicine and specializing in LDN therapy, I've seen this medication change lives for many Lyme patients. It's safe, it's affordable (typically $30-50 per month from a compounding pharmacy), and it works with your body's own healing mechanisms. Is it right for everyone? No. Is it a standalone cure? Absolutely not. But as part of a comprehensive functional medicine approach to chronic Lyme, LDN deserves serious consideration—especially for those who've tried everything else without success. If you're struggling with persistent Lyme symptoms and wondering whether LDN might help, I encourage you to find an integrative medicine practitioner who understands both Lyme disease and LDN therapy. You deserve a partner who will look at the whole picture and work with you toward real healing. That's what functional medicine is all about—and that's why I love what I do. Meet Dr. Yoon Hang Kim MD Integrative and Functional Medicine Expert and LDN Authority At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References 1. Aucott JN, Rebman AW, Crowder LA, Kortte KB. Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here? Qual Life Res. 2013;22(1):75-84. 2. Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. 5. Soloski MJ, Crowder LA, Lahey LJ, et al. Serum inflammatory mediators as markers of human Lyme disease activity. PLoS One. 2014;9(4):e93243. 6. Aucott JN, Soloski MJ, Rebman AW, et al. CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome. Clin Vaccine Immunol. 2016;23(9):757-766. 9. Bihari B. Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med. 2013;19(2):56-65. 10. Zagon IS, McLaughlin PJ. Opioid growth factor and the treatment of human pancreatic cancer: a review. World J Gastroenterol. 2014;20(9):2218-2223. 11. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. 12. Cant R, Dalgleish AG, Allen RL. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets. Front Immunol. 2017;8:809. 13. Parkitny L, Younger J. Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia. Biomedicines. 2017;5(2):16. 14. Kui N, Raki V, Verko R, et al. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells. Int J Mol Sci. 2021;22(16):8429. 15. Tichauer C. LDN and Lyme Disease II. Presented at: LDN Research Trust 2017 Conference; 2017. 16. Zagon IS, McLaughlin PJ. Endogenous opioids and the growth regulation of a neural tumor. Life Sci. 1988;43(16):1313-1318. 17. 2012 Integrative Healthcare Symposium: Treating the Pain of Lyme Disease. P T. 2012;37(4):247-249. 18. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia. Arthritis Rheum. 2013;65(2):529-538. 19. Arbi NS, et al. Efficacy and safety of low-dose naltrexone for fibromyalgia: a systematic review and meta-analysis. Korean J Pain. 2024;37(4):339-352. 21. Elsegood L. The LDN Book. Chelsea Green Publishing; 2016. 22. Li Z, You Y, Griffin N, et al. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases. Int Immunopharmacol. 2018;61:178-184. 23. Horowitz RI. Why Can't I Get Better? Solving the Mystery of Lyme and Chronic Disease. St. Martin's Press; 2013. Disclaimer: This article is for educational purposes only and does not constitute medical advice. Low-dose naltrexone is not FDA-approved for Lyme disease. Always consult with a qualified healthcare provider before starting any new treatment.

Yoon Hang "John" Kim, MD, MPH Low-Dose Naltrexone LDN in Multiple Sclerosis: An Integrative Medicine Functional Medicine Perspective Low-Dose Naltrexone in Multiple Sclerosis: An Integrative Medicine Perspective About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com LDN MS Integrative Medicine Functional Medicine Introduction Multiple sclerosis (MS) remains one of the most challenging autoimmune disorders affecting the central nervous system, characterized by chronic inflammation, progressive demyelination, and cumulative neurological disability. For the estimated 2.8 million people living with MS worldwide, the journey involves navigating complex treatment decisions, managing unpredictable symptoms, and maintaining quality of life despite disease progression (Walton et al., 2020). While conventional disease-modifying therapies (DMTs) form the cornerstone of MS management, many patients and practitioners within integrative medicine and functional medicine are exploring complementary approaches that address the multifaceted nature of this condition. Low-dose naltrexone (LDN), typically administered at 0.5 to 4.5 mg nightly, has emerged as one such option garnering significant attention. Originally developed at standard doses (50 mg) for opioid and alcohol dependence, naltrexone at low doses appears to exert fundamentally different pharmacological effects—shifting from sustained opioid receptor blockade to transient receptor modulation with potential immunomodulatory consequences. This article examines the current evidence base for LDN in MS, explores proposed mechanisms of action, and contextualizes its role within a comprehensive integrative medicine framework. Understanding Low-Dose Naltrexone: Mechanisms and Rationale The therapeutic rationale for LDN diverges substantially from its parent compound's original application. At standard doses, naltrexone provides continuous opioid receptor antagonism lasting approximately 24 hours. In contrast, low-dose naltrexone at 4.5 mg produces a brief blockade lasting only 4 to 6 hours, typically during sleep. This transient blockade triggers a compensatory upregulation of endogenous opioid production—including beta-endorphin and met-enkephalin—and may increase opioid receptor sensitivity (Brown & Panksepp, 2009). This interaction with opioid receptors also influences immune system balance, as LDN's effects on opioid pathways can modulate inflammatory responses. From a functional medicine perspective, this mechanism is particularly relevant. Endogenous opioids play crucial roles in immune regulation, with beta-endorphin affecting natural killer cell activity, T-lymphocyte proliferation, and inflammatory cytokine production. The endorphin hypothesis suggests that many autoimmune conditions, including MS, may involve relative deficiencies in endogenous opioid tone, contributing to immune dysregulation and chronic inflammation (Zagon & McLaughlin, 2017). Additionally, LDN appears to modulate glial cell activity within the central nervous system. Microglia and astrocytes, when chronically activated, contribute substantially to neuroinflammation and may perpetuate the inflammatory cascade seen in MS. Research suggests that LDN may attenuate this glial activation, potentially reducing the production of pro-inflammatory cytokines and neurotoxic mediators (Younger & Mackey, 2014). This dual action—peripheral immune modulation combined with central nervous system effects—aligns well with integrative medicine approaches that seek to address disease processes at multiple levels simultaneously. Clinical Evidence: What the Research Demonstrates Randomized Controlled Trials The clinical investigation of LDN in MS, while still evolving, has produced several noteworthy studies. Cree et al. (2010) conducted a pilot crossover trial examining 4.5 mg LDN in 80 patients with clinically definite MS over an 8-week period. Despite some attrition affecting statistical power, the study yielded important findings: LDN demonstrated excellent tolerability with no serious adverse events, and participants showed significant improvements in mental health-related quality of life measures. Specifically, improvements were documented in the SF-36 Mental Component Summary and the Perceived Deficits Questionnaire, suggesting potential benefits for cognitive and psychological well-being—domains that significantly impact daily functioning. A subsequent trial by Sharafaddinzadeh et al. (2010) employed a 17-week crossover design in 96 patients with relapsing-remitting or secondary progressive MS. While confirming LDN's favorable safety profile, this study found limited benefit across most quality of life domains. However, a modest improvement in health perception scores emerged, prompting the investigators to recommend longer-duration studies. Gironi et al. (2008) specifically examined LDN in primary progressive MS (PPMS), a subtype historically resistant to many interventions. Their Phase II pilot trial followed 40 patients over six months, demonstrating safety and tolerability alongside intriguing secondary findings: significant reduction in spasticity and elevated beta-endorphin levels, providing some mechanistic validation for the endorphin hypothesis. These results hold particular relevance for integrative medicine practitioners, as spasticity management represents a significant unmet need in progressive MS. Beyond MS, LDN has been studied in other autoimmune and inflammatory conditions. Research in Crohn's disease has shown clinical improvement in active disease, and studies in fibromyalgia and rheumatoid arthritis suggest LDN may help modulate immune responses. These findings support LDN as a potential adjunctive option for various chronic inflammatory conditions. Long-Term Observational Data Observational studies provide insights into real-world effectiveness and long-term outcomes. Ludwig et al. (2016) conducted a 10-year retrospective review of patients treated with LDN, either as monotherapy or adjunctively with glatiramer acetate. Participants demonstrated stable health outcomes without exacerbation of symptoms or significant MRI changes over this extended period. The authors characterized the regimen as safe, non-toxic, and cost-effective—attributes particularly valued within functional medicine practice. A pharmacoepidemiological analysis by Raknes et al. (2017) examined medication patterns among 341 Norwegian MS patients following LDN initiation. The study found no reduction in the use of standard DMTs or symptomatic medications after starting LDN, suggesting that patients and physicians viewed LDN as complementary rather than as a replacement for conventional therapies. This observation aligns with the integrative medicine philosophy of combining evidence-based conventional treatments with complementary approaches. Positioning LDN Within an Integrative Medicine Framework For practitioners of integrative medicine and functional medicine, LDN represents one component within a comprehensive approach to MS management. Rather than viewing it as an alternative to conventional DMTs, LDN may be most appropriately considered as an adjunctive therapy targeting specific symptomatic domains—particularly quality of life, mental health, fatigue, and spasticity—where conventional options may fall short. The functional medicine model emphasizes identifying root causes of disease, supporting the body's inherent healing mechanisms, and personalizing treatment. LDN fits within this framework through its proposed action on endogenous regulatory systems rather than through direct immunosuppression. By potentially restoring opioid system balance and modulating neuroinflammation, LDN may support the body's own regulatory capacity—a principle central to functional medicine philosophy. A comprehensive integrative approach to MS often includes dietary modifications, stress management, physical activity, and addressing environmental factors—all of which can support medical treatments and improve overall wellness. LDN can be one element within this broader therapeutic strategy. From a practical standpoint, LDN offers several advantages: it is generally well-tolerated, relatively inexpensive (typically $35–70 monthly from compounding pharmacies), does not require monitoring bloodwork, and appears to have minimal drug interactions with most MS medications. Common side effects—vivid dreams and transient sleep disturbance during the initial weeks—are typically mild and self-limiting. Organizational and Expert Perspectives Major MS organizations have addressed LDN with measured positions. The National Multiple Sclerosis Society (2024) recognizes the popularity of off-label LDN use but notes that most supporting evidence remains anecdotal or derived from small trials. They advise patients to discuss LDN with their neurologists, particularly regarding potential interactions with opioid medications. The MS Trust (2020) acknowledges reported benefits among some individuals while emphasizing that LDN is unlicensed for MS in the UK and lacks robust clinical evidence. Their guidance appropriately cautions that LDN should not replace proven disease-modifying therapies. The LDN Research Trust (2020) provides a more optimistic assessment, summarizing practitioner reports indicating potential benefits for fatigue, pain, and spasticity. They position LDN as a complementary approach that may contribute to disease stabilization through immune modulation and endorphin enhancement, while acknowledging the need for larger confirmatory trials. Compounding Pharmacy Considerations Since LDN is unavailable in commercial formulations at therapeutic doses, it requires preparation by compounding pharmacies. This specialized process involves creating precisely customized doses—typically 1.5 mg to 4.5 mg—tailored to individual patient needs. The quality of compounded LDN matters significantly. Reputable compounding pharmacies adhere to standards established by the United States Pharmacopeia (USP) and state boards of pharmacy, ensuring medications are prepared in controlled environments using pharmaceutical-grade ingredients. Patients and healthcare providers should consider pharmacies with accreditation from organizations such as the Pharmacy Compounding Accreditation Board (PCAB). When selecting a compounding pharmacy, it's reasonable to inquire about batch testing procedures, ingredient sourcing, and established protocols. Consistent compounding practices help maintain stable therapeutic levels and minimize variability between refills—an important consideration for ongoing therapy. Clinical Considerations and Patient Selection For clinicians considering LDN, several practical points merit attention. Patient selection should account for current opioid use, as LDN is contraindicated in patients taking opioid medications due to potential precipitation of withdrawal. A washout period of 7 to 14 days is typically recommended before initiating LDN in patients transitioning off opioids. Dosing typically begins at 1.5 mg nightly, with gradual titration to the target dose of 4.5 mg over 2 to 4 weeks. This approach minimizes initial side effects and allows for individual optimization. Some patients find their best response at doses below 4.5 mg, highlighting the importance of individualized titration—a hallmark of integrative medicine practice. LDN may also benefit symptoms beyond those traditionally studied, including brain fog and chronic pain conditions such as complex regional pain syndrome. Emerging evidence suggests potential metabolic benefits, including improved insulin sensitivity, which may be relevant for patients with concurrent metabolic concerns. "I want to highlight three real people who have beaten MS. First, Linda—founder of one of the most prominent LDN support groups—who has lived this journey herself. Second, one of my own patients whose neurologist confirmed she is now in remission; she has stopped all her MS medications through our combined integrative approach with LDN. And third, Dr. Terry Wahls, who reversed her own MS with her modified paleo diet and functional medicine principles. These aren't theoretical possibilities—these are real outcomes from real people." Yoon Hang Kim MD Conclusion Low-dose naltrexone represents a promising adjunctive option within the integrative medicine toolkit for multiple sclerosis. Current evidence consistently demonstrates safety and tolerability, with some studies suggesting meaningful improvements in quality of life, mental health, and spasticity. While efficacy data remain mixed and larger randomized controlled trials are needed, LDN's favorable risk profile and low cost make it a reasonable consideration for patients seeking complementary approaches. Within a functional medicine framework, LDN's proposed mechanism of supporting endogenous opioid and immune regulatory systems aligns with the broader philosophy of working with the body's inherent healing capacity. For patients and practitioners navigating MS treatment, LDN offers an additional option that may enhance quality of life when integrated thoughtfully with established conventional therapies. As with all therapeutic decisions, open communication between patients and healthcare providers remains essential. Patients considering LDN should discuss it with their neurologist and integrative medicine practitioner to ensure appropriate coordination of care. Low-Dose Naltrexone in Multiple Sclerosis: An Integrative Medicine Perspective At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Yoon Hang Kim MD MPH Expert in Integrative & Functional Medicine References Brown, N., & Panksepp, J. (2009). Low-dose naltrexone for disease prevention and quality of life. Medical Hypotheses, 72 (3), 333–337. https://doi.org/10.1016/j.mehy.2008.06.048 Cree, B. A. C., Kornyeyeva, E., & Goodin, D. S. (2010). Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology, 68 (2), 145–150. https://doi.org/10.1002/ana.22006 Gironi, M., Martinelli, V., Brambilla, E., Furlan, R., Panerai, A. E., Comi, G., & Sacerdote, P. (2008). A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Multiple Sclerosis, 14 (8), 1076–1083. https://doi.org/10.1177/1352458508095828 LDN Research Trust. (2020). Low dose naltrexone for MS . https://ldnresearchtrust.org/low-dose-naltrexone-ms Ludwig, M. D., Turel, A. P., Eller, M. E., & Smith, T. (2016). Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis. Multiple Sclerosis Journal – Experimental, Translational and Clinical, 2 (3), 1–9. https://doi.org/10.1177/2055217316672242 MS Trust. (2020). Low dose naltrexone (LDN) . https://mstrust.org.uk/a-z/low-dose-naltrexone-ldn National Multiple Sclerosis Society. (2024). Low-dose naltrexone usage in multiple sclerosis . https://www.nationalmssociety.org/news-and-magazine/momentum-magazine/living-well/low-dose-naltrexone-usage-in-ms Raknes, G., Småbrekke, L., & Nilsen, K. B. (2017). Low dose naltrexone in multiple sclerosis: Effects on medication use. PLOS ONE, 12 (11), Article e0187423. https://doi.org/10.1371/journal.pone.0187423 Sharafaddinzadeh, N., Moghtaderi, A., Kashipazha, D., Majdinasab, N., & Shalbafan, M. R. (2010). The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: A randomized placebo-controlled trial. Multiple Sclerosis, 16 (8), 964–969. https://doi.org/10.1177/1352458510366854 Walton, C., King, R., Rechtman, L., Kaye, W., Leray, E., Marrie, R. A., ... & Baneke, P. (2020). Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Multiple Sclerosis Journal, 26 (14), 1816–1821. https://doi.org/10.1177/1352458520970841 Younger, J., & Mackey, S. (2014). Low-dose naltrexone for chronic pain: A systematic review of the clinical evidence. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2 Zagon, I. S., & McLaughlin, P. J. (2017). Endogenous opioids in the etiology and treatment of multiple sclerosis. In Multiple sclerosis: Perspectives in treatment and pathogenesis  (pp. 125–142). Codon Publications. https://doi.org/10.15586/codon.multiplesclerosis.2017.ch8

Role of Probiotics in Integrative Medicine and Functional Medicine: Evidence-Based Role of Probiotics in Integrative and Functional Medicine: A Clinical Review Yoon Hang Kim, MD, MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Abstract Probiotics have become a cornerstone of integrative medicine and functional medicine practice, offering evidence-based options for gastrointestinal conditions and broader health optimization. This clinical review synthesizes current evidence from randomized controlled trials, systematic reviews, and meta-analyses examining probiotic efficacy for antibiotic-associated diarrhea, irritable bowel syndrome, ulcerative colitis, and pouchitis. The integrative medicine approach emphasizes strain-specific and disease-specific selection, individualized patient assessment, and integration within comprehensive treatment protocols. Clinical evidence supports targeted probiotic interventions when appropriately matched to patient presentations, with demonstrated efficacy for specific strains including Lactobacillus rhamnosus  GG, Saccharomyces boulardii , and high-concentration multi-strain preparations containing the De Simone Formulation. Introduction The integration of probiotic therapy into clinical practice represents one of the most significant advances in integrative medicine over the past two decades. Defined as live microorganisms that confer health benefits when administered in adequate amounts, probiotics have evolved from complementary therapy to evidence-based intervention for multiple gastrointestinal conditions. Within the functional medicine framework, probiotics serve as foundational tools for addressing the underlying dysbiosis that contributes to chronic disease—and they're increasingly central to how we manage complex, ongoing conditions. Those of us practicing integrative medicine have long recognized the therapeutic potential of targeted microbiome modulation. Where conventional medicine often addresses symptoms in isolation, integrative medicine combines standard care with complementary approaches to create treatment strategies that recognize gut health as central to overall wellness. This aligns with the functional medicine principle of treating root causes rather than simply managing downstream effects. The clinical evidence supporting probiotic efficacy has matured substantially, with high-quality systematic reviews and meta-analyses now guiding our recommendations. However, a critical principle has emerged: probiotic effects are fundamentally strain-specific and disease-specific. Benefits demonstrated with one strain or formulation cannot be extrapolated to others, even within the same species. This specificity demands that clinicians maintain detailed knowledge of which preparations are supported for which indications. Prevention of Antibiotic-Associated Diarrhea Antibiotic-associated diarrhea represents one of the strongest evidence-based applications for probiotic therapy in integrative medicine practice. Antibiotics disrupt commensal gut flora, creating conditions that favor pathogenic overgrowth and osmotic imbalance. This results in diarrhea in 5-39% of patients depending on the antibiotic class and patient population. From a functional medicine perspective, this iatrogenic dysbiosis is a preventable consequence of necessary antimicrobial therapy—and probiotics can help treat or prevent these complications by restoring microbial balance during and after antibiotic use. Multiple high-quality meta-analyses demonstrate that co-administration of probiotics with antibiotics reduces AAD incidence by approximately 37-51%, with effects most pronounced when probiotic therapy starts early in the antibiotic course. The landmark systematic review by Hempel and colleagues published in JAMA analyzed 82 randomized controlled trials and established level A evidence for probiotic prophylaxis against AAD. Two strains have demonstrated particularly robust efficacy: Lactobacillus rhamnosus  GG and Saccharomyces boulardii . These organisms show consistent benefit across pediatric and adult populations aged 18-64 years. The American Academy of Family Physicians now recommends probiotic co-administration for AAD prevention—a reflection of how this evidence has been integrated into mainstream practice guidelines. It's worth noting that evidence for AAD prevention is less robust in elderly populations over 65 years. The PLACIDE trial, a large multicenter randomized controlled trial published in The Lancet, found no significant benefit from a multi-strain Lactobacillus  and Bifidobacterium  preparation in older hospitalized patients receiving antibiotics. This finding underscores the importance of patient selection and the limitations of extrapolating efficacy across populations—a principle central to both integrative medicine and functional medicine practice. Probiotic Therapy in Irritable Bowel Syndrome Irritable bowel syndrome exemplifies the complex, multifactorial conditions where integrative medicine and functional medicine approaches offer distinct advantages over conventional symptomatic management. The functional medicine model conceptualizes IBS as a manifestation of underlying gut-brain axis dysfunction, intestinal permeability alterations, and microbiome imbalance—not simply a diagnosis of exclusion to be managed with antispasmodics. Systematic reviews demonstrate that probiotics provide modest but clinically meaningful improvement in global IBS symptoms, including abdominal pain, bloating, and flatulence. Meta-analyses suggest approximately 21% reduction in persistent symptoms compared with placebo, though effects vary considerably by strain, preparation, and IBS subtype. Multi-strain preparations generally outperform single-strain products, reflecting the complexity of the microbiome ecosystem we're trying to restore. Evidence for specific strains remains mixed, illustrating the challenges of translating research findings into clinical practice. Lactobacillus plantarum  299v has been evaluated in multiple randomized trials with conflicting results. The trial by Ducrotté and colleagues demonstrated significant symptom improvement, while other studies found no benefit over placebo. This variability highlights the need for individualized treatment selection—something we emphasize in both integrative medicine and functional medicine. From my perspective, probiotic therapy for IBS shouldn't be considered in isolation. It's one component of a comprehensive protocol addressing dietary triggers, stress management, motility support, and intestinal barrier function. The functional medicine approach emphasizes identifying and treating the unique constellation of factors contributing to each patient's presentation rather than applying standardized protocols uniformly. When we address these factors together, we see meaningful improvements in quality of life and long-term health. Adjunctive Therapy in Ulcerative Colitis and Pouchitis The application of probiotics in inflammatory bowel disease represents a sophisticated integration of microbiome science with conventional gastroenterological care—precisely the synthesis that defines modern integrative medicine. While probiotic therapy cannot replace standard pharmacological management of ulcerative colitis, high-quality evidence supports its role as effective adjunctive treatment in appropriate patients. High-concentration multi-strain probiotics containing the De Simone Formulation (currently available as Visbiome and historically formulated in VSL#3 prior to 2016) have demonstrated efficacy in inducing and maintaining remission in mild-to-moderate ulcerative colitis when combined with standard therapies. The specificity of this evidence is critical: these results apply to this particular formulation and cannot be extrapolated to other probiotic products regardless of marketing claims or apparent similarity in strain composition. Other probiotics may not provide the same benefits. Randomized controlled trials by Bibiloni et al. (2005), Sood et al. (2009), and Tursi et al. (2010) report remission rates approaching 77% in patients with active mild-to-moderate disease receiving the De Simone Formulation as adjunctive therapy. These findings have been incorporated into clinical practice guidelines, representing successful translation of integrative medicine research into mainstream gastroenterology recommendations. Pouchitis following ileal pouch-anal anastomosis represents perhaps the strongest indication for probiotic therapy in gastroenterology. The seminal work by Gionchetti and colleagues established that high-concentration multi-strain probiotics effectively prevent pouchitis recurrence and maintain remission in this challenging patient population. For functional medicine practitioners managing post-surgical patients, this is an essential evidence-based intervention. The Principle of Strain and Disease Specificity A foundational principle for anyone prescribing probiotics is that efficacy is both strain-specific and disease-specific. The systematic review and meta-analysis by McFarland and colleagues published in Frontiers in Medicine provides compelling evidence that benefits cannot be generalized across strains, even within the same species. A Lactobacillus  strain effective for AAD prevention may offer no benefit for IBS or inflammatory bowel disease. This has profound implications for clinical practice. The functional medicine approach demands precise matching of probiotic strains to clinical indications, avoiding the common but inappropriate practice of recommending generic "probiotic supplements" without attention to formulation specifics. We need to verify that recommended products contain the specific strains supported by clinical trial evidence for the intended indication. Emerging research suggests potential probiotic applications beyond gastrointestinal health, including cognitive function and mental health outcomes. Umbrella reviews of meta-analyses by Xie et al. (2021) indicate moderate-quality evidence for cognitive benefits, though further randomized controlled trials are needed before we can make definitive recommendations. This expanding evidence base reflects what integrative medicine has long recognized: gut health influences systemic function through multiple pathways, including the gut-brain axis. Probiotics and Immune Function In functional medicine and integrative medicine practice, we recognize that immune function doesn't exist in isolation—it's deeply connected to gut health. The gastrointestinal tract houses roughly 70% of the body's immune tissue, making the relationship between beneficial bacteria and immune response more than theoretical. Clinical research has shown that specific probiotic strains can modulate immune function in meaningful ways. Strains including Lactobacillus acidophilus , Bifidobacterium breve , and Bifidobacterium longum  have demonstrated effects on immune markers and may help reduce susceptibility to certain infections. These beneficial bacteria work by competing with pathogens for resources and attachment sites, producing antimicrobial compounds, and signaling to immune cells in the gut mucosa. The National Center for Complementary and Integrative Health acknowledges probiotics as a legitimate area of research for immune support, though they appropriately note that evidence varies by strain and condition. This is consistent with what we see in clinical practice: some patients with chronic conditions—fibromyalgia, chronic fatigue, autoimmune disorders—respond well to targeted probiotic protocols as part of comprehensive treatment, while others see minimal benefit. The key is individualized assessment. From a practical standpoint, I recommend that patients work with their healthcare team to select probiotic products based on clinical evidence rather than marketing. Not all probiotic supplements are created equal—quality and potency vary significantly between products, and the strains that work for one condition may not work for another. A thorough evaluation that considers the whole patient—including stress, diet, sleep, and existing conditions—remains essential for developing effective treatment plans. Safety Considerations Probiotics demonstrate excellent safety profiles in healthy individuals, with adverse events typically limited to minor gastrointestinal symptoms including transient bloating, gas, or altered bowel habits during initial therapy. These effects generally resolve with continued use as the microbiome adjusts. However, certain populations require heightened caution. Serious adverse events, while rare, have been reported in immunocompromised patients, those with central venous catheters, critically ill patients, and individuals with severe acute pancreatitis. The functional medicine emphasis on comprehensive patient assessment becomes essential when determining probiotic candidacy in complex or medically fragile patients. Clinical judgment should prioritize strains with documented safety profiles for the specific patient population. The NIH Office of Dietary Supplements maintains updated safety information that clinicians should consult when managing higher-risk patients. As with any intervention, patients should discuss probiotic use with their healthcare provider, particularly if they have underlying health conditions or are taking other medications. Conclusion Probiotic therapy represents a mature, evidence-based intervention within the integrative medicine and functional medicine toolkit. The strongest evidence supports specific applications: AAD prevention with L. rhamnosus  GG or S. boulardii , adjunctive ulcerative colitis management with high-concentration De Simone Formulation products, and pouchitis prevention following surgery. The functional medicine principle of individualized treatment selection applies directly to probiotic prescribing. Clinicians must match specific strains to specific indications based on clinical trial evidence rather than relying on generic recommendations or marketing claims. The integrative medicine approach positions probiotic therapy within comprehensive treatment protocols addressing diet, lifestyle, stress, and other factors contributing to gastrointestinal dysfunction. As research continues to elucidate microbiome-health relationships, applications for probiotic therapy will likely expand. Practitioners should maintain current knowledge of evolving evidence while adhering to the fundamental principle that probiotic benefits are strain-specific and disease-specific—a principle that protects patients from ineffective interventions and ensures optimal outcomes. At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): A randomised, double-blind, placebo-controlled, multicentre trial. Lancet . 2013;382(9900):1249-1257. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol . 2005;100(7):1539-1546. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol . 2012;18(30):4012-4018. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology . 2000;119(2):305-309. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: A systematic review and meta-analysis. JAMA . 2012;307(18):1959-1969. McFarland LV, Ship N, Auclair J, Millette M. Strain-specificity and disease-specificity of probiotic efficacy: A systematic review and meta-analysis. Front Med . 2018;5:124. National Institutes of Health, Office of Dietary Supplements. Probiotics: Health professional fact sheet. Updated 2025. https://ods.od.nih.gov/factsheets/Probiotics-HealthProfessional/ Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol . 2009;7(11):1202-1209. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: A double-blind, randomized, placebo-controlled study. Am J Gastroenterol . 2010;105(10):2218-2227. Xie C, Li X, Zhu J, Sun J, Wang X. Probiotics and cognitive-related health outcomes: An umbrella review of meta-analyses of randomized controlled trials. Nutr Rev . 2021;79(11):1259-1269.

Understanding Menopause Supplements: An Evidence-Based Guide to Benefits, Limitations, and Informed Decision-Making Understanding Menopause Supplements: About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Introduction Menopause represents a universal biological transition, marking the permanent end of menstrual periods and natural fertility. Confirmed retrospectively after 12 consecutive months without menstruation, menopause typically occurs between ages 45 and 55, though individual variation is substantial (National Institute on Aging, 2024; World Health Organization, 2024). This life stage, while entirely normal, often brings challenging symptoms that significantly impact quality of life, driving many individuals to seek relief through various therapeutic approaches. While hormone therapy (HT) remains the most effective treatment for menopausal symptoms, concerns about potential risks—particularly following the Women's Health Initiative findings—have prompted substantial interest in complementary and alternative approaches. Dietary supplements have emerged as popular options, with research suggesting that certain plant-based compounds may offer modest symptom relief for some individuals. However, it is essential to approach these products with realistic expectations: benefits tend to be ingredient-specific and generally smaller than those achieved with conventional hormone therapy (Franco et al., 2016; Pokushalov et al., 2025). This comprehensive review examines the current scientific evidence surrounding menopause supplements, providing healthcare consumers and practitioners with the information necessary to make informed decisions about integrating these products into a broader wellness strategy. The Biology of Menopause: Understanding What Changes Menopause occurs when the ovaries cease releasing eggs and estrogen production declines substantially, resulting in the permanent cessation of menstrual periods and the end of natural reproductive capacity (National Institute on Aging, 2024; World Health Organization, 2024). Natural menopause is diagnosed clinically after 12 consecutive months of amenorrhea without another identifiable medical cause or hormonal intervention. The menopausal transition, commonly termed perimenopause, may span several years and is characterized by fluctuating and eventually declining levels of estrogen and progesterone. These hormonal shifts drive the constellation of symptoms many individuals experience, including vasomotor symptoms (hot flashes and night sweats), sleep disturbances, mood changes, cognitive concerns, and genitourinary changes such as vaginal dryness (National Institute on Aging, 2024; World Health Organization, 2024). The severity, duration, and specific manifestation of these symptoms vary considerably among individuals, influenced by genetic, lifestyle, and environmental factors. Beyond immediate symptom burden, the decline in estrogen has long-term health implications. Accelerated bone loss following menopause increases osteoporosis and fracture risk, while the cardiovascular advantage women typically enjoy over men gradually diminishes as estrogen levels fall (World Health Organization, 2024). These considerations underscore the importance of a comprehensive approach to perimenopausal and postmenopausal health that addresses both symptomatic relief and long-term disease prevention. Evaluating the Evidence: Do Menopause Supplements Work? The scientific literature on menopause supplements presents a complex picture, with evidence varying substantially by ingredient, formulation, dose, and study quality. Meta-analyses and systematic reviews provide the most reliable synthesis of available data, though even these analyses reveal considerable heterogeneity in findings. Phytoestrogens and Plant-Based Therapies A landmark 2016 systematic review and meta-analysis published in JAMA examined 62 studies encompassing 6,653 women and found that phytoestrogen supplementation was associated with modest reductions in hot flash frequency and vaginal dryness scores compared to placebo. However, the same analysis found no significant reduction in night sweats, and the authors noted substantial heterogeneity in study quality, with 74% of included trials demonstrating high risk of bias in three or more areas (Franco et al., 2016). Similarly, a Cochrane systematic review examining phytoestrogens for menopausal vasomotor symptoms concluded that no conclusive evidence supports the effectiveness of phytoestrogen supplements in reducing hot flash frequency or severity in perimenopausal or postmenopausal women. The review noted a strong placebo effect across most trials, with placebo groups experiencing symptom reductions ranging from 1% to 59% (Lethaby et al., 2013). These findings highlight both the potential for modest benefit and the importance of tempering expectations. Combination Botanical Formulations More recent research has examined combination approaches. A 2025 randomized, double-blind, placebo-controlled trial evaluated the effects of a supplement combining black cohosh, soy isoflavones, and SDG lignans in 96 postmenopausal women over 90 days. The treatment group demonstrated statistically significant improvements across all Menopause Rating Scale domains: somatic symptoms (54.3% difference), psychological symptoms (54.3% difference), urogenital symptoms (37.3% difference), and total score (48.0% difference). The safety profile was favorable, with few adverse events reported (Pokushalov et al., 2025). While these results are encouraging, they represent a single trial with a relatively small sample size and short duration. Replication in larger, longer-term studies across diverse populations will be necessary before definitive conclusions can be drawn. Nevertheless, such findings suggest that thoughtfully formulated combination products may offer greater benefit than single-ingredient supplements. Key Ingredients: What the Science Supports Vasomotor Symptom Support Among the most studied botanicals for menopausal vasomotor symptoms are black cohosh (Actaea racemosa), soy isoflavones, and SDG lignans (secoisolariciresinol diglucoside, derived primarily from flaxseed). These compounds have demonstrated varying degrees of efficacy in clinical trials, though results remain inconsistent across studies (Franco et al., 2016; Pokushalov et al., 2025). Other plant-based options sometimes incorporated into menopause formulas include red clover, sage, and dong quai, though evidence supporting these ingredients is generally weaker or more inconsistent, positioning them as secondary or adjunctive options (Franco et al., 2016; Lethaby et al., 2013). Mood, Sleep, and Stress Support Ingredients such as magnesium, L-theanine, and certain adaptogens (notably ashwagandha) are frequently incorporated into menopause supplements targeting sleep quality and stress management. While these compounds have demonstrated effects in broader anxiety and sleep research, menopause-specific data remain limited. Individuals experiencing significant mood or sleep disturbances should discuss these symptoms with a healthcare provider, as they may warrant targeted evaluation and treatment. Bone and Cardiometabolic Health Foundational nutrients for bone health in midlife and beyond include vitamin D, calcium, and increasingly, vitamin K2. These become particularly important as estrogen decline accelerates bone resorption (National Institute on Aging, 2024; World Health Organization, 2024). Omega-3 fatty acids may support cardiovascular and inflammatory health, which gains relevance as cardiometabolic risk increases following menopause (World Health Organization, 2024). These nutrients, while not directly targeting acute menopausal symptoms, address important long-term health considerations that should be part of comprehensive perimenopausal care. Choosing Wisely: A Framework for Supplement Selection Match Formulation to Primary Concerns For hot flashes and night sweats, look for products containing clinically studied doses of standardized soy isoflavones, black cohosh, or combination formulas similar to those evaluated in controlled trials. Avoid products that obscure ingredient amounts within proprietary blends, as dose matters substantially for efficacy (Pokushalov et al., 2025). For sleep, mood, and stress concerns, select formulations that specify evidence-based doses and provide clear information about potential interactions with prescription medications, particularly antidepressants or anxiolytics. Prioritize Quality and Transparency Third-party verification marks (such as USP or NSF certification) provide some assurance that labeled ingredients and doses match actual product contents and that contamination risks are minimized. Avoid products making disease-treatment claims, incorporating stimulant blends, or combining numerous herbs at low, unstudied doses. Remember that dietary supplements are not FDA-approved to treat menopause and may interact with medications or affect individuals with liver disease (World Health Organization, 2024). Seek Professional Guidance Prefer products and ingredients supported by randomized controlled trials or systematic reviews specifically conducted in peri- or postmenopausal populations, rather than relying solely on anecdotal testimonials (Franco et al., 2016; Pokushalov et al., 2025). Most importantly, discuss any new supplement with a clinician familiar with menopause care—whether a gynecologist, menopause specialist, or integrative/functional medicine practitioner—particularly if there is a history of hormone-sensitive cancers, clotting disorders, liver disease, or polypharmacy (National Institute on Aging, 2024; World Health Organization, 2024). When Supplements May Be Appropriate Individuals may reasonably consider supplement use when menopausal symptoms affect daily life but they cannot, do not wish to, or are not yet candidates for systemic hormone therapy—for example, during early symptom evaluation, with mild symptom burden, or when certain risk profiles make HT less suitable (National Institute on Aging, 2024; World Health Organization, 2024). Supplements may also serve as adjuncts to lifestyle modifications including dietary optimization, regular physical activity, and stress management strategies (World Health Organization, 2024). Importantly, supplements work best as components of a broader, individualized care plan developed collaboratively with healthcare providers who can monitor safety, assess for drug-supplement interactions, and evaluate treatment response over time. They are not substitutes for comprehensive medical evaluation or, when indicated, evidence-based pharmacological therapy. Conclusion Menopause supplements occupy a nuanced space in symptom management—neither entirely ineffective nor comparable to hormone therapy in efficacy. Current evidence suggests modest benefits for certain ingredients and combinations, particularly for vasomotor symptoms, though results remain inconsistent and effect sizes generally smaller than those achieved with conventional treatment. For individuals seeking complementary approaches, evidence-based ingredient selection, attention to product quality, and professional oversight represent the foundations of safe and rational supplement use. As research continues to evolve—with newer trials examining combination formulas and longer-term outcomes—our understanding of these products will undoubtedly deepen. In the interim, informed consumers and practitioners can navigate this landscape by maintaining realistic expectations, prioritizing high-quality evidence, and integrating supplements thoughtfully within comprehensive perimenopausal and postmenopausal care strategies. At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Yoon Hang Kim MD Integrative & Functional Medicine Physician References Franco, O. H., Chowdhury, R., Troup, J., Voortman, T., Kunutsor, S., Kavousi, M., Oliver-Williams, C., & Muka, T. (2016). Use of plant-based therapies and menopausal symptoms: A systematic review and meta-analysis. JAMA, 315 (23), 2554–2563. https://doi.org/10.1001/jama.2016.8012 Lethaby, A., Marjoribanks, J., Kronenberg, F., Roberts, H., Eden, J., & Brown, J. (2013). Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database of Systematic Reviews, (12), Article CD001395. https://doi.org/10.1002/14651858.CD001395.pub4 National Institute on Aging. (2024, October 16). What is menopause? U.S. Department of Health and Human Services. https://www.nia.nih.gov/health/menopause/what-menopause Pokushalov, E., Ponomarenko, A., Garcia, C., Kasimova, L., Pak, I., Shrainer, E., Romanova, A., Kudlay, D., Johnson, M., & Miller, R. (2025). Assessing the combined effects of black cohosh, soy isoflavones, and SDG lignans on menopausal symptoms: A randomized, double-blind, placebo-controlled clinical trial. European Journal of Nutrition, 64 (3), 138. https://doi.org/10.1007/s00394-025-03588-y World Health Organization. (2024, October 16). Menopause [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/menopause

By Yoon Hang "John" Kim, MD, MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Niacinamide, also known as nicotinamide, represents one of the most versatile and well-tolerated supplements in integrative medicine. As the amide form of vitamin B3, this water-soluble nutrient serves as a precursor to nicotinamide adenine dinucleotide (NAD⁺) and its phosphorylated derivative (NADP⁺)—essential coenzymes involved in over 500 redox reactions critical for energy metabolism, DNA repair, and cellular resilience. Unlike its sibling molecule nicotinic acid (niacin), niacinamide does not induce the characteristic cutaneous flushing that many patients find intolerable, rendering it a preferable option for therapeutic use across multiple clinical applications. Understanding the Biochemistry: Why Niacinamide Matters The clinical significance of niacinamide stems from its foundational role in cellular energy production. NAD⁺ levels decline with age, chronic stress, and disease states, creating a cellular energy deficit that manifests across multiple organ systems. Niacinamide efficiently replenishes NAD⁺ pools via the salvage pathway, maintaining cellular energy production through glycolysis, fatty acid oxidation, and the tricarboxylic acid cycle. Beyond energy metabolism, NAD⁺ activates poly(ADP-ribose) polymerase (PARP) enzymes essential for DNA repair and sirtuins involved in gene regulation and longevity pathways. This dual mechanism—supporting both cellular energy and genomic stability—positions niacinamide as a foundational intervention in protocols addressing metabolic dysregulation, chronic inflammation, and age-related cellular decline. The distinction from niacin bears clinical importance. While both compounds share identical vitamin functions, their pharmacological profiles diverge significantly. Niacin has high affinity for the G-protein-coupled receptor HM74A, triggering prostaglandin release and the vasodilation responsible for the uncomfortable flushing reaction. Niacinamide lacks this receptor affinity, making it extremely well-tolerated topically and orally—clinical tests demonstrate no stinging at concentrations up to 10% and no irritation up to 5% in dermatological applications. Antioxidant and Anti-Inflammatory Mechanisms In functional medicine practice, niacinamide's value extends beyond NAD⁺ repletion to encompass robust antioxidant and anti-inflammatory effects. Oxidative stress—the generation of reactive oxygen species (ROS) exceeding cellular antioxidant capacity—represents a core driving factor in chronic disease and aging. Niacinamide attenuates oxidative burden through multiple mechanisms. By maintaining favorable NAD⁺/NADPH ratios, niacinamide decreases NADPH oxidase expression and activity, reducing superoxide radical concentrations. It increases superoxide dismutase levels and enhances catalase activity, transforming hydrogen peroxide back into oxygen and water. Additionally, niacinamide demonstrates direct scavenger activity, particularly against hydroxyl radicals. The anti-inflammatory properties operate through PARP-1 regulation, COX-2 inhibition, and modulation of NF-κB-mediated transcription. Clinical studies demonstrate reduced expression of pro-inflammatory cytokines including TNF-α, IL-1, IL-6, and IL-8, alongside increased production of anti-inflammatory mediators such as IL-10. This cytokine modulation is dose-dependent and has been validated in human clinical trials showing decreased IL-1αRA/IL-1α inflammatory skin biomarkers after topical application of 5% niacinamide formulations. Dermatological Applications: Beyond Cosmetic Benefits Topical and oral niacinamide has accumulated robust evidence in dermatology, representing perhaps the best-documented clinical application of this nutrient. Skin Barrier Enhancement and Photoaging Niacinamide strengthens the epidermal barrier by boosting ceramide synthesis through activation of serine palmitoyl transferase and accelerating keratinocyte differentiation. Clinical studies in Caucasian populations demonstrate significant reductions in yellowing, wrinkling, red blotchiness, and hyperpigmented spots associated with aging facial skin. The anti-yellowing effect stems from niacinamide's ability to reduce advanced glycation end products (AGEs) that accumulate in the cutaneous extracellular matrix. The skin lightening activity operates not through tyrosinase inhibition or reduced melanin synthesis, but rather by blocking melanosome transfer from melanocytes to surrounding keratinocytes. This mechanism makes niacinamide effective for hyperpigmentation disorders including melasma, axillary hyperpigmentation, lentigo senilis, and post-inflammatory hyperpigmentation. Compared to hydroquinone, niacinamide takes longer to demonstrate clinical efficacy but causes fewer adverse effects, making it suitable for longer treatment protocols. Acne and Inflammatory Skin Conditions For acne vulgaris, niacinamide addresses multiple pathogenic factors simultaneously: it reduces sebum production through mechanisms possibly involving HCA2 receptor activation (via conversion to niacin), exerts antimicrobial activity against Cutibacterium acnes , and suppresses inflammation. Clinical trials demonstrate efficacy levels comparable to clindamycin in anti-inflammatory activity, with concentrations of 2-4% showing particular effectiveness in oily skin types. The antimicrobial activity extends beyond direct bactericidal effects to include stimulation of antimicrobial peptide (AMP) synthesis and enhanced neutrophil function. Niacinamide activates innate immune pathways and enhances the activity of cathelicidin LL-37 through membrane modulation effects. Skin Cancer Chemoprevention Perhaps the most compelling dermatological application involves oral niacinamide for nonmelanoma skin cancer prevention. A landmark Phase III randomized trial published in the New England Journal of Medicine  demonstrated that 500 mg twice daily significantly reduced the rate of new nonmelanoma skin cancers (basal cell and squamous cell carcinomas) and actinic keratoses in high-risk individuals with sun-damaged skin. The chemopreventive mechanism operates through enhanced DNA repair of UV radiation-induced damage in keratinocytes and melanocytes. Niacinamide prevents post-UV exposure declines in cellular energy and repletes ATP to irradiated cells, facilitating nucleotide excision repair. Additionally, niacinamide reduces UV-induced immunosuppression and decreases inflammatory macrophages that may contribute to carcinogenesis. Memorial Sloan Kettering Cancer Center notes that while these protective effects against UV exposure are significant, niacinamide does not replace sunscreen and does not protect against sunburn. The cancer-preventive benefits appear specific to high-risk populations with documented sun damage. Musculoskeletal Applications: Osteoarthritis A double-blind, placebo-controlled pilot study published in Inflammation Research  demonstrated promising results for niacinamide in osteoarthritis management. In 72 patients treated for 12 weeks, niacinamide improved global arthritis impact by 29% compared to a 10% worsening in placebo subjects. Joint mobility increased by 4.5 degrees over controls, erythrocyte sedimentation rate decreased by 22%, and patients reduced their NSAID use by 13%. The mechanism likely involves NAD⁺-dependent modulation of chondrocyte metabolism, nitric oxide pathway regulation, and anti-inflammatory effects on joint tissues. While this represents a single pilot study requiring replication, the results align with niacinamide's established anti-inflammatory profile and suggest potential as an adjunctive intervention in integrative osteoarthritis protocols. Metabolic and Renal Applications Phosphorus Management in Chronic Kidney Disease Niacinamide inhibits intestinal phosphate absorption via the NaPi-2b cotransporter, effectively lowering serum phosphorus in hemodialysis patients when used adjunctively with phosphate binders. Meta-analyses support its efficacy and tolerability in this population, with potential benefits for mineral bone disorder management. However, increased risk of thrombocytopenia has been noted in hemodialysis patients, warranting careful monitoring. Beta-Cell Protection in Type 1 Diabetes Early investigations explored niacinamide for beta-cell preservation in newly diagnosed type 1 diabetes, though large trials have shown modest or inconsistent results for insulin secretion preservation. This application remains investigational. Neurological Considerations Historical orthomolecular approaches explored high-dose niacinamide for psychiatric conditions including schizophrenia and anxiety, based on observations linking pellagra to neuropsychiatric symptoms. Contemporary research focuses more on neuroprotective effects in degenerative models. Recent clinical trials demonstrate improvements in inner retinal and visual function in patients treated for glaucoma, suggesting potential applications in neurodegenerative conditions where NAD⁺ depletion and mitochondrial dysfunction play pathogenic roles. Safety Profile and Clinical Considerations Niacinamide is generally well-tolerated at therapeutic doses up to 3 grams daily. The most common adverse effects are mild gastrointestinal symptoms including nausea. Headache, fatigue, and dizziness have been reported at higher doses, and liver toxicity is possible with very high intake. Important Cautions Drug Interactions:  Niacinamide may increase blood levels of carbamazepine, necessitating monitoring in patients on this anticonvulsant. Cardiovascular Considerations:  Recent research has identified associations between a terminal metabolite of excess niacin supplementation and increased major adverse cardiovascular events (MACE). While this applies more directly to niacin than niacinamide, patients with cardiovascular history should discuss supplementation with their cardiologist. Thrombocytopenia Risk:  Meta-analyses of hemodialysis patients suggest increased risk of low platelets with niacinamide use. Not Interchangeable with Niacin:  Despite metabolic conversion between these compounds, their supplemental effects and side effect profiles differ significantly. Unauthorized substitution of niacin for niacinamide has caused unexpected flushing reactions. Practical Dosing Considerations Dosing depends on the clinical indication: Dermatological applications (topical):  2-5% formulations are typical, with 4-5% most commonly used in anti-aging protocols Skin cancer chemoprevention:  500 mg twice daily (1000 mg total daily) Osteoarthritis:  The pilot study used divided doses totaling approximately 3 grams daily General antioxidant/anti-inflammatory support:  Lower doses of 500-1000 mg daily are reasonable starting points As with any supplement protocol, individualization based on patient history, concurrent medications, and treatment goals remains essential. Integrative Medicine Perspective From an integrative medicine standpoint, niacinamide exemplifies the principle of working with the body's intrinsic repair mechanisms rather than against them. By supporting NAD⁺-dependent cellular processes that naturally decline with age and disease, niacinamide addresses upstream metabolic factors rather than simply suppressing downstream symptoms. Its remarkably broad safety profile, low cost, and compatibility with conventional therapies make it a practical adjunct in protocols addressing chronic inflammation, cardiometabolic disorders, skin health, and age-related decline. The multiple mechanisms of action—antioxidant, anti-inflammatory, barrier-supportive, and DNA repair-enhancing—allow it to address the interconnected pathophysiology characteristic of chronic conditions. Conclusion Niacinamide represents a well-characterized, evidence-based intervention with applications spanning dermatology, rheumatology, nephrology, and potentially neurology and oncology. Its safety profile permits use in diverse patient populations, though specific cautions apply to those on certain medications or with cardiovascular or renal conditions. As with all integrative interventions, optimal outcomes depend on appropriate patient selection, realistic expectations, and integration with comprehensive care plans. The strongest evidence supports dermatological applications, particularly skin cancer chemoprevention in high-risk individuals, where Phase III trial data provides robust clinical guidance. About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in utilizing LDN or Low Dose Naltrexone for treating autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com References Marques C, et al. Mechanistic Insights into the Multiple Functions of Niacinamide: Therapeutic Implications and Cosmeceutical Applications in Functional Skincare Products. Antioxidants (Basel) . 2024;13(4):425. Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res . 1996;45(7):330-334. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med . 2015;373(17):1618-1626. Boo YC. Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation. Antioxidants . 2021;10:1315. Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci . 2004;26:231-238. Thompson BC, Surjana D, Halliday GM, et al. Nicotinamide enhances repair of ultraviolet radiation-induced DNA damage in primary melanocytes. Exp Dermatol . 2014;23(7):509-511. Rolfe HM. A review of nicotinamide: treatment of skin diseases and potential side effects. J Cosmet Dermatol . 2014;13(4):324-328. Memorial Sloan Kettering Cancer Center. About Herbs: Nicotinamide. Updated February 2023. Ferrell M, Wang Z, Anderson JT, et al. A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk. Nat Med . 2024;30(2):424-434. Zhang Y, Ma T, Zhang P. Efficacy and safety of nicotinamide on phosphorus metabolism in hemodialysis patients: A systematic review and meta-analysis. Medicine (Baltimore) . 2018;97(41):e12731. Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any supplement regimen. Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician specializing in chronic conditions and preventive care. Learn more at Direct Integrative Care .

Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Evidence-Based Review: Supplements for Male Sexual Function - Integrative Medicine Functional Medicine Perspective by Yoon Hang Kim MD MPH Evidence-Based Review: Supplements for Male Sexual Function - Integrative Medicine Functional Medicine Perspective San Antonio TX Introduction Erectile dysfunction affects an estimated 150 million men globally, with projections suggesting approximately 322 million men will be affected by 2025. The prevalence increases significantly with age—from 2–9% in men aged 40–49 years to 50–100% in men over 70. Beyond ED, concerns like low libido and hormonal shifts are common and can significantly impact quality of life. While PDE-5 inhibitors like sildenafil remain first-line therapy, many patients seek natural alternatives due to side effects, cost, drug interactions, or personal preference. This review synthesizes current clinical evidence from systematic reviews, meta-analyses, and randomized controlled trials examining supplements for male sexual function. As with any integrative approach, realistic expectations and shared decision-making remain essential. In my practice, I focus on identifying root causes of dysfunction and creating personalized treatment plans—considering physical, metabolic, hormonal, and even emotional factors that influence sexual vitality. Panax Ginseng: The Strongest Evidence Base Korean red ginseng ( Panax ginseng ) has the most robust evidence among herbal supplements for erectile dysfunction. A 2025 systematic review and meta-analysis of 14 RCTs involving 1,227 men published in the Journal of Herbal Medicine  demonstrated significant improvements across multiple domains of sexual function. Key Findings The meta-analysis found significant effects on erectile function (SMD = 1.20, 95% CI: 0.64–1.76), orgasmic function (SMD = 1.09), sexual desire (SMD = 1.02), intercourse satisfaction (SMD = 1.48), and overall satisfaction (SMD = 0.93). Notably, ginseng also improved serum testosterone levels (SMD = 0.54, 95% CI: 0.04–1.05). The 2022 Cochrane systematic review concluded that ginseng may enhance men's self-reported capacity for sexual intercourse with little to no effect on adverse events. A double-blind, placebo-controlled trial with 143 patients found significant improvements across all five IIEF domains after 8 weeks of 2,000 mg/day tissue-cultured mountain ginseng extract. How It Works Ginsenosides are believed to enhance nitric oxide synthesis in the corpus cavernosum and improve penile blood flow. Additional mechanisms include antioxidant effects, modulation of the hypothalamic-pituitary-gonadal axis, and direct effects on vascular smooth muscle relaxation. Practical Recommendations Typical dosing ranges from 900–3,000 mg/day of standardized Korean red ginseng extract for 4–12 weeks. Side effects are generally mild, including headache and gastrointestinal discomfort. Evidence quality remains moderate—ginseng shouldn't be considered equivalent to PDE-5 inhibitors, but it's a reasonable option for men seeking natural support. L-Arginine: The Nitric Oxide Precursor L-arginine is the physiological substrate for nitric oxide synthase, making it a logical choice for ED given NO's central role in penile erection. A 2019 systematic review and meta-analysis of 10 RCTs involving 540 patients demonstrated that arginine supplementation significantly improved erectile dysfunction compared to placebo. Clinical Evidence The meta-analysis found that L-arginine at dosages of 1,500–5,000 mg/day significantly improved ED (OR 3.37, 95% CI: 1.29–8.77, p = 0.01). Significant improvements were observed in IIEF subdomain scores for erectile function, intercourse satisfaction, orgasmic function, and overall satisfaction—though sexual desire scores remained unchanged. A 2022 multicentre, double-blind RCT published in the Journal of Endocrinological Investigation  examined high-dose L-arginine (6 g/day) for 3 months in patients with vasculogenic ED. Results showed significant improvements in IIEF-6 scores (p < 0.0001) and cavernous arteries peak systolic flow velocity in patients with mild-moderate ED. Notably, 74% of patients improved their ED severity category. The Pycnogenol Combination A 2023 meta-analysis in Frontiers in Endocrinology  examined the combination of L-arginine with Pycnogenol (French maritime pine bark extract). The combination produced significant improvements across all IIEF domains—erectile function (MD 8.9), intercourse satisfaction (MD 4.96), orgasmic function, overall satisfaction, and sexual desire. The synergy likely stems from Pycnogenol's ability to enhance endothelial NO synthase activity while L-arginine provides the substrate. Practical Recommendations Effective doses range from 2,500–6,000 mg/day, often divided into multiple doses. L-arginine works best for mild-moderate ED and in patients with vascular etiology. The adverse effect rate was 8.3% (vs 2.3% for placebo), primarily gastrointestinal symptoms. Consider combining with Pycnogenol (40–120 mg/day) for enhanced efficacy. Ashwagandha: The Stress-Libido Connection Ashwagandha ( Withania somnifera ) is increasingly recognized for its effects on male sexual function, particularly when stress is a contributing factor. This is where I find it most useful in clinical practice. Chronic stress and elevated cortisol can disrupt hormonal balance, suppress testosterone production, and dampen libido. Ashwagandha's adaptogenic properties help modulate the stress response, which can indirectly support sexual function. Clinical Evidence A 2022 randomized, double-blind, placebo-controlled study published in Health Science Reports  examined ashwagandha root extract (600 mg/day) in 50 adult males with low sexual desire for 8 weeks. Results showed significant improvements in total DISF-M scores (mean difference −9.8; 95% CI: −10.73 to −8.87; p < 0.0001). Serum testosterone levels also increased significantly (mean difference −66.52 ng/dL; p < 0.0001). A 2019 crossover study in aging, overweight males found that 8 weeks of ashwagandha extract was associated with an 18% greater increase in DHEA-S (p = 0.005) and 14.7% greater increase in testosterone (p = 0.010) compared to placebo. An earlier pilot study in psychogenic ED demonstrated that ashwagandha (2,000 mg TID for 60 days) improved erectile function and sexual satisfaction in men with psychologically-mediated dysfunction. How It Works Ashwagandha's withanolides have structural similarity to testosterone and may influence GnRH expression via GABA receptor modulation. Its cortisol-lowering effects may indirectly support testosterone production by reducing HPA axis suppression of the reproductive axis. By supporting healthy stress hormone levels, ashwagandha addresses one of the most overlooked contributors to sexual dysfunction. Practical Recommendations Standard dosing is 300–600 mg/day of standardized root extract (typically KSM-66 or Sensoril formulations) for 8–12 weeks. Ashwagandha is particularly suited for men with stress-related low libido, suboptimal testosterone within normal range, or concurrent anxiety and fatigue. Tribulus Terrestris: Traditional Use Meets Modern Research Tribulus terrestris  has been used traditionally as an aphrodisiac across multiple cultures. The 2023 meta-analysis in Nutrients  identified Tribulus as one of the supplements able to improve male sexual function based on pooled RCT data. Clinical Evidence While much of the robust data comes from female studies, male-specific research shows promising results. The meta-analysis identified Tribulus as demonstrating significant effects on erectile function compared to placebo, though evidence quality remains low to moderate due to heterogeneous study designs. The active constituent protodioscin is believed to influence the hypothalamic-pituitary axis, though direct testosterone elevation has not been consistently demonstrated in human studies. Some researchers suggest the mechanism may involve increased sensitivity to androgens rather than elevated levels. Practical Recommendations Typical dosing ranges from 250–750 mg/day of standardized extract for 4–12 weeks. Side effects are generally mild gastrointestinal symptoms. Given the limited high-quality human data specifically in men, I consider Tribulus an adjunctive therapy rather than primary treatment. Maca: Andean Adaptogen for Desire Maca ( Lepidium meyenii ) is an Andean cruciferous plant traditionally used to enhance fertility and libido. What's interesting about maca is that its effects appear to be hormone-independent—it improves desire without significantly changing testosterone levels. Clinical Evidence A 2023 RCT published in the World Journal of Men's Health  examined maca in patients with late-onset hypogonadism symptoms. After 12 weeks of 3,000 mg/day, significant improvements were observed in AMS (Aging Males' Symptoms), IIEF, and IPSS scores compared to placebo. The ADAM positive rate significantly decreased (p < 0.0001) in the maca group. An earlier systematic review of 4 RCTs found limited but positive evidence for maca improving sexual desire in healthy men and erectile function in men with mild ED (IIEF-5 MD 1.13, 95% CI: 0.64–1.61, p < 0.0001). A pilot study examining SSRI-induced sexual dysfunction found that 3.0 g/day of maca produced significant improvements in ASEX scores, with particular benefits for libido—making it a useful option for patients on antidepressants. Practical Recommendations Effective doses range from 1,500–3,000 mg/day of dried maca root powder for 8–12 weeks. Benefits for sexual desire may appear as early as 8 weeks. Maca is particularly suited for improving desire and may help with SSRI-induced sexual dysfunction. Fenugreek: Testosterone Support and Libido Fenugreek ( Trigonella foenum-graecum ) has emerged as a promising option for supporting testosterone levels and male sexual function, with several well-designed RCTs demonstrating efficacy. Clinical Evidence A 2020 meta-analysis found that fenugreek extract has a significant positive effect on total serum testosterone levels. A 2016 double-blind RCT of Testofen (standardized fenugreek extract) in 120 healthy men aged 43–70 demonstrated significant decreases in AMS scores and improvements in sexual function—including morning erections and frequency of sexual activity—after 12 weeks of 600 mg/day. An earlier RCT in 60 healthy males found that 600 mg/day of Testofen for 6 weeks produced significant improvements in sexual arousal and orgasm, with 81% reporting improvement in libido and 63% improvement in sexual performance quality. A 2018 study in the World Journal of Men's Health  examining a mixed extract of fenugreek and Lespedeza cuneata  in testosterone deficiency syndrome found significant improvements in total and free testosterone, as well as erectile function. How It Works Fenugreek saponins may inhibit aromatase and 5α-reductase, reducing conversion of testosterone to estrogen and DHT respectively. This preserves bioavailable testosterone. Diosgenin, a steroidal saponin in fenugreek, serves as a precursor for steroid hormone synthesis. Practical Recommendations Standard dosing is 500–600 mg/day of standardized fenugreek extract for 6–12 weeks. Fenugreek is particularly suited for aging males with symptoms of androgen decline and men interested in both sexual function and exercise performance benefits. Saffron: Rapid Onset for Erectile Function Saffron ( Crocus sativus ) has shown particularly promising results for erectile dysfunction, with some studies demonstrating improvements in as little as 10 days. This rapid onset makes it unique among the supplements reviewed. Clinical Evidence A 2018 meta-analysis found that saffron had a significantly positive effect on all dimensions of the IIEF questionnaire: erectile function (MD = 5.36), orgasmic function (MD = 1.12), overall satisfaction (MD = 1.23), intercourse satisfaction (MD = 2.18), and sexual desire (MD = 0.78)—all statistically significant. A 2022 double-blind, placebo-controlled RCT in 62 men with ED found that 30 mg/day of saffron for 6 weeks produced improvements in erectile function scores of 6.14 points (95% CI: 4.97–7.30)—exceeding the minimal clinically important difference. The adverse event profile was similar to placebo. Notably, a pilot study found that just 10 days of saffron (200 mg/day) produced significant improvements in IIEF-15 total scores (22.15 to 39.20, p < 0.001) with increased number and duration of erectile events on nocturnal penile tumescence testing. SSRI-Induced Sexual Dysfunction:  A 4-week RCT in men with fluoxetine-related sexual dysfunction found that saffron (30 mg/day) produced significantly greater improvements in erectile function (p < 0.001) and intercourse satisfaction compared to placebo. This makes saffron particularly attractive for patients on antidepressants. How It Works Saffron's active components (crocin, crocetin, and safranal) possess antioxidant, anti-inflammatory, and neuromodulatory properties. The serotonergic effects may explain efficacy in SSRI-induced dysfunction. Antioxidant activity may protect endothelial function and support NO bioavailability. Practical Recommendations Effective doses are 15–30 mg twice daily (30–60 mg/day total) for 4–10 weeks. Saffron appears particularly suited for SSRI-induced sexual dysfunction and mild ED. Cautions include potential interactions with serotonergic medications. Doses above 5 g/day are considered unsafe. Antioxidant Supplementation: The Emerging Evidence A 2025 meta-analysis published in the World Journal of Men's Health  examined 23 double-blind, placebo-controlled trials involving 1,583 men with ED treated with various antioxidant supplements for a median of 12 weeks. The pooled analysis found that antioxidant supplementation significantly improved erectile function with a mean difference of 5.5 points (95% CI: 3.7–7.3; p < 0.001) on the IIEF-EF scale. In subgroup analyses, Pycnogenol and L-arginine combinations showed the most significant benefits. This reinforces what we understand about ED pathophysiology—oxidative stress and endothelial dysfunction play significant roles, and vascular health is foundational to sexual function. Maintaining a diet rich in antioxidants supports these pathways. Important Caveats and Clinical Considerations Evidence Quality:  While these supplements show promising results, evidence quality remains predominantly low to moderate. None should be considered equivalent to PDE-5 inhibitors for established ED. Placebo Response:  Sexual function studies consistently show substantial placebo effects (up to 40%), which complicates interpretation of modest treatment effects. Product Quality:  The 2023 analysis found that 80% of marketed products didn't meet criteria for expected efficacy based on active ingredient doses. I recommend reputable manufacturers using standardized extracts. Underlying Conditions:  ED is often a sentinel marker for cardiovascular disease and metabolic dysfunction. Appropriate medical evaluation should precede or accompany any supplement regimen. A thorough evaluation—including hormone levels and thyroid function—is essential to identify root causes. Lifestyle Foundation:  Exercise, diet, sleep quality, smoking cessation, and weight management remain foundational. Blood pressure, metabolic health, and cardiovascular fitness all directly impact sexual function. Supplements work best as part of a comprehensive approach addressing root causes, not as standalone solutions. Evidence-Based Review: Supplements for Male Sexual Function - Integrative Medicine Functional Medicine Perspective San Antonio TX Practical Summary by Presentation Mild-Moderate Vasculogenic ED:  L-arginine (2,500–6,000 mg/day) ± Pycnogenol; Panax ginseng (900–3,000 mg/day) Stress-Related Low Libido:  Ashwagandha (300–600 mg/day); Maca (1,500–3,000 mg/day) SSRI-Induced Sexual Dysfunction:  Saffron (30 mg BID); Maca (3,000 mg/day) Aging Males Symptoms/Low-Normal Testosterone:  Fenugreek (500–600 mg/day); Ashwagandha (300–600 mg/day) Rapid Onset Needed:  Saffron (may show effects within 10 days) Meet Dr Kim 2026 Meet Yoon Hang Kim MD - expert in integrative & functional medicine and LDN expert At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Key References Petre GC et al. Dietary Supplements for Erectile Dysfunction: Analysis of Marketed Products, Systematic Review, Meta-Analysis and Rational Use. Nutrients . 2023;15(17):3677. Ramasamy R et al. Antioxidant Supplementation for Erectile Dysfunction: Systematic Review and Meta-Analysis. World J Mens Health . 2025;43(1). Tian Y et al. Efficacy of L-arginine and Pycnogenol in the treatment of male erectile dysfunction: a systematic review and meta-analysis. Front Endocrinol . 2023;14:1211720. Menafra D et al. Long-term high-dose l-arginine supplementation in patients with vasculogenic erectile dysfunction. J Endocrinol Invest . 2022;45(5):941-961. Rhim HC et al. The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systemic Review and Meta-Analysis. J Sex Med . 2019;16(2):223-234. Lee HW et al. Ginseng for Erectile Dysfunction: A Cochrane Systematic Review. World J Mens Health . 2022;40(2):264-269. Chauhan S et al. Effect of standardized root extract of ashwagandha on well-being and sexual performance in adult males. Health Sci Rep . 2022;5(4):e741. Shin BC et al. Maca (L. meyenii) for improving sexual function: a systematic review. BMC Complement Altern Med . 2010;10:44. Choi YS et al. Efficacy and Safety of Maca in Patients with Late-Onset Hypogonadism. World J Mens Health . 2023;41(3). Rao A et al. Testofen reduces age-related symptoms of androgen decrease and improves sexual function. Aging Male . 2016;19:134-142. Steels E et al. Physiological aspects of male libido enhanced by standardized Trigonella foenum-graecum extract. Phytother Res . 2011;25:1294-1300. Modabbernia A et al. Effect of saffron on fluoxetine-induced sexual impairment in men. Psychopharmacology . 2012;223(4):381-388. Shamsa A et al. Evaluation of Crocus sativus L. (saffron) on male erectile dysfunction. Phytomedicine . 2009;16(8):690-693. Maleki-Saghooni N et al. A systematic review and meta-analysis of clinical trials on saffron effectiveness and safety on erectile dysfunction. Iran J Basic Med Sci . 2018;21(6):554-563. Herbal dietary supplements for erectile dysfunction: A systematic review and meta-analysis. J Herb Med . 2025. Disclaimer: This review is for educational purposes only. Consultation with a healthcare professional is essential prior to initiating any supplement for sexual dysfunction. Individual responses vary, and supplements may interact with medications or underlying conditions. Erectile dysfunction can be a marker of significant cardiovascular disease requiring medical evaluation.

Evidence-Based Review: Supplements for Female Sexual Function A Practical Guide for Integrative and Functional Medicine Perspective Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim is a board-certified integrative medicine physician with over 20 years of clinical experience. He completed his integrative medicine fellowship at the University of Arizona under Dr. Andrew Weil and holds certifications in preventive medicine, medical acupuncture, and integrative/holistic medicine. Through his telemedicine practice, Dr. Kim specializes in autoimmune conditions, chronic pain, integrative oncology, and complex conditions including fibromyalgia, chronic fatigue, MCAS, and mold toxicity. He is the author of three books and more than 20 articles, and has helped establish integrative medicine programs at institutions nationwide. Professional:   www.yoonhangkim.com  | Clinical:   www.directintegrativecare.com Evidence-Based Review: Supplements for Female Sexual Function A Practical Guide for Integrative and Functional Medicine Perspective Edited by Yoon Hang Kim MD MPH Introduction: Why This Matters Let's be honest—female sexual dysfunction is one of those topics that often gets pushed to the margins of clinical conversations. Yet it affects roughly 40% of women worldwide and can profoundly impact quality of life, intimate relationships, and overall well-being. In my two decades of clinical practice, I've found that many women feel dismissed when they bring up concerns about low libido, difficulty with arousal, or other sexual health issues. This is where integrative medicine and functional medicine approaches shine. Rather than simply prescribing a pill and sending patients on their way, we have the opportunity to explore root causes—hormonal imbalances, chronic stress, nutritional deficiencies, relationship dynamics, and mental health factors like anxiety and depression. Sometimes the solution is a supplement. Often, it's a combination of targeted interventions, lifestyle changes, and addressing psychological contributors. What follows is my synthesis of the current evidence on natural supplements for female sexual function. I've tried to be both thorough and practical—giving you the data you need to have informed conversations with your patients while being honest about the limitations of the research. The Current State of Evidence The landmark 2021 meta-analysis by Sha'ari and colleagues, published in Phytomedicine , remains our best starting point. Their systematic review of 20 studies identified Tribulus terrestris  and Panax ginseng  as showing the most robust evidence for improving female sexual function. Since then, we've seen additional research on ashwagandha, saffron, fenugreek, and maca—though the evidence quality remains predominantly low to moderate across the board. Before diving into individual supplements, I want to emphasize something important: substantial placebo effects (up to 40% in some trials) complicate interpretation of these studies. Sexual function is deeply tied to psychological factors, expectations, and relationship dynamics. This doesn't mean supplements don't work—it means we need to be thoughtful about setting realistic expectations with patients. Tribulus terrestris: The Strongest Evidence If I had to pick one supplement with the most compelling data, it would be Tribulus terrestris . The Sha'ari meta-analysis found large effect sizes for overall sexual function (SMD = 1.12), sexual desire (SMD = 1.08), arousal (SMD = 1.03), and orgasm (SMD = 0.51)—all statistically significant compared to placebo. What the Individual Trials Show A double-blind RCT with 67 premenopausal women with hypoactive sexual desire disorder found that just 7.5 mg/day of Tribulus extract for 4 weeks produced significant improvements in total FSFI scores and the desire domain (p < 0.001). That's a remarkably low dose showing meaningful effects. For postmenopausal women, an RCT using 750 mg/day for 120 days showed improvements in both FSFI and Sexual Quotient scores. Interestingly, serum testosterone levels didn't significantly change—suggesting the mechanism may not be straightforward testosterone modulation as many assume. An open-label assessment of 120 women found that 88% showed improvement in total FSFI scores, with DHEA levels increasing significantly while testosterone remained stable. This hints at adrenal pathway involvement rather than direct gonadal effects. How It Probably Works Tribulus contains protodioscin, a steroidal saponin that may influence the hypothalamic-pituitary axis, potentially affecting LH and FSH secretion. The DHEA elevation suggests adrenal modulation. Animal studies hint at effects on follicular development, though human data is limited. Practical Recommendations Typical dosing ranges from 250–750 mg/day in divided doses for 4–16 weeks. Side effects are generally mild GI symptoms (gastric discomfort, occasional reflux). The 2020 systematic review by Martimbianco emphasized that evidence certainty remains "very low"—so shared decision-making with patients about realistic expectations is essential. Ashwagandha: The Stress-Libido Connection Ashwagandha ( Withania somnifera ) is one of my go-to recommendations, particularly for women where stress seems to be suppressing libido. We now have three well-designed RCTs specifically examining its effects on female sexual function. The Clinical Evidence 2015 Pilot Study (n=50): Using 600 mg/day of high-concentration root extract (HCARE) for 8 weeks, researchers found significant improvements versus placebo in total FSFI (p < 0.001), arousal, lubrication, orgasm, and satisfaction. Notably, the desire domain did not  reach significance—an important nuance for patient counseling. 2022 KSM-66 Study (n=80): This trial showed statistically significant improvement in all  FSFI subscales including desire (p < 0.0001). Quality of life scores also improved. The KSM-66 extract may have advantages over other formulations. 2025 RCT (n=62): The most recent study confirmed improvements in FSFI (p = 0.002), Perceived Stress Scale (p = 0.0009), and SF-12 quality of life (p = 0.044). The correlation between stress reduction and sexual function improvement supports the adaptogenic mechanism. Why It Works Ashwagandha's adaptogenic properties reduce cortisol and normalize HPA axis function. Chronic stress is a major libido killer—elevated cortisol suppresses gonadal function and shifts the body into "survival mode" rather than "thriving mode." By addressing the stress response, ashwagandha may restore conditions favorable to healthy sexual function. Its anxiolytic and antidepressant effects likely contribute as well. Dosing and Safety Standard dosing is 300–600 mg/day of standardized root extract for 8+ weeks. Side effects are rare and mild (occasional nausea, drowsiness). Long-term safety studies in rats showed a no-observed-adverse-effect level of 2000 mg/kg/day, supporting a favorable safety profile at human therapeutic doses. Saffron: Especially for SSRI-Induced Dysfunction Saffron ( Crocus sativus ) deserves special attention for women experiencing antidepressant-induced sexual dysfunction—a frustratingly common clinical scenario. A meta-analysis found significant effects on arousal (p = 0.028) and lubrication (p = 0.03). Key Studies A 2022 three-center RCT enrolled 68 women with severe FSD. Those receiving 15 mg saffron twice daily showed 62% improvement from baseline at 6 weeks, with superiority over placebo in desire, lubrication, and satisfaction domains. The time × treatment interaction favored saffron (p = 0.050). For fluoxetine-induced dysfunction specifically, earlier studies showed saffron improved arousal, lubrication, and pain—domains particularly affected by SSRIs. A 2024 trial combining saffron (30 mg/day) with vitamin E (50 mg) showed overall sexual function improvement (AMD 4.6, p < 0.001), with benefits sustained 4 weeks post-intervention. Mechanism Saffron's bioactive compounds (crocin, safranal) enhance dopamine and glutamate neurotransmission—potentially counteracting SSRI effects on these pathways. Its antidepressant and anxiolytic properties address psychological aspects, while antinociceptive effects may reduce pain-related discomfort. Nitric oxide release promotes genital blood flow. Practical Use Typical dosing is 15–30 mg/day for 4–8 weeks. Within therapeutic ranges, saffron is well-tolerated. Cost can be a barrier given saffron's expense, but standardized supplements are more affordable than culinary-grade saffron. Panax Ginseng: Meta-Analytic Support Korean red ginseng has solid meta-analytic support for arousal (SMD = 0.54, p = 0.014) and desire (SMD = 0.59, p < 0.001) in the Sha'ari analysis. Clinical Data A crossover RCT with 32 menopausal women found Korean red ginseng 3 g/day significantly improved sexual arousal (p = 0.006), with benefits in desire, lubrication, orgasm, and satisfaction. A premenopausal study showed FSFI improvements after 8 weeks, though the difference versus placebo didn't reach significance—highlighting substantial placebo effects in this population. How It Works Ginsenosides enhance nitric oxide synthesis in vascular endothelium, producing vasodilatory effects that improve genital blood flow. Antioxidant protection of vascular endothelium and potential modulation of dopamine and acetylcholine neurotransmitters may also contribute. Dosing Standard dosing is 1–3 g/day of Korean red ginseng for 8+ weeks. Generally well-tolerated; occasional gastric discomfort reported. Maca: Best for SSRI-Induced Dysfunction Maca root ( Lepidium meyenii ) shows its strongest effects in women with SSRI-induced sexual dysfunction—a niche where we desperately need options. The Evidence A dose-finding pilot study found 3 g/day maca (versus 1.5 g/day) significantly improved ASEX and MGH-SFQ scores in women with SSRI-induced dysfunction, with libido specifically improving on the ASEX item (p = 0.028). The higher dose appears important. A double-blind follow-up showed higher remission rates with maca versus placebo, with postmenopausal women showing particularly robust responses—though researchers noted this might relate to age rather than menopausal status specifically. Mechanism Mystery Interestingly, maca doesn't appear to have direct androgenic activity and doesn't significantly affect serum reproductive hormone levels. The mechanism remains unclear but may involve non-hormonal pathways affecting energy, mood, and central nervous system function. Sometimes the clinical effect matters more than understanding exactly why it works. Practical Points Use 1.5–3 g/day for 6–12 weeks. The higher dose (3 g/day) appears more effective. Maca is generally well-tolerated with minimal side effects. Available in various forms including gelatinized powder, which may be easier to digest. Fenugreek: Hormonal Effects Fenugreek ( Trigonella foenum-graecum ) is interesting because it actually moves hormones—something most botanicals don't reliably do. Clinical Studies Libifem® Study (n=80): 600 mg/day of standardized fenugreek seed extract in healthy menstruating women with self-reported low libido significantly increased estradiol and free testosterone levels versus placebo. Sexual desire and arousal improved. FenuSMART Study (n=48): 250 mg twice daily for 42 days showed 41.6% of participants reporting relief from sexual problems and irritability, with significant increases in estradiol (p = 0.040), free testosterone (p = 0.025), and total testosterone (p = 0.012). Mechanism Fenugreek contains saponins with phytoestrogenic activity. Effects appear stronger in women with suboptimal baseline hormone levels—suggesting it may work by normalizing deficiencies rather than pushing levels supraphysiological. This makes it potentially useful for perimenopause and hormone balance optimization. Dosing Typical dosing is 500–600 mg/day of standardized extract for 6–8 weeks. Generally well-tolerated. May cause maple syrup-like body odor in some individuals (harmless but can be surprising for patients). L-Arginine Combinations: Variable Results A 2021 systematic review by Cieri-Hutcherson evaluated seven studies on L-arginine for HSDD. Six of seven reported improvements in FSFI scores—but the devil is in the details. Key Findings Combination products like ArginMax (L-arginine with Panax ginseng, Ginkgo biloba, damiana, vitamins and minerals) show more consistent benefits than L-arginine monotherapy. ArginMax studies showed 73.5% of women improved in satisfaction with overall sex life versus 37.2% with placebo (p < 0.01). Results vary by menopausal status: premenopausal women showed improved desire and satisfaction; perimenopausal women showed improved intercourse frequency and vaginal dryness; postmenopausal women primarily showed increased desire (51% vs 8%, p = 0.008). In cancer survivors, ArginMax didn't improve sexual function but did improve overall quality of life—a reminder that sexual function improvements don't always follow general well-being improvements. Practical Notes L-arginine enhances nitric oxide production for improved blood flow. Combination products likely work through multiple mechanisms. ArginMax has been shown to exhibit no estrogenic activity on bioassay, making it suitable for women avoiding hormone therapy. Standard dosing is 3 capsules twice daily for 4–12 weeks. Intranasal Oxytocin: Not Ready for Primetime Despite theoretical appeal, intranasal oxytocin hasn't lived up to expectations. A key randomized trial by Muin and colleagues (2015) found no significant superiority over placebo in improving FSFI scores in women with HSDD. The placebo group showed up to 40% improvement—highlighting just how powerful expectation and attention effects can be in sexual function research. While endogenous oxytocin naturally rises during arousal and orgasm and contributes to bonding and satisfaction, exogenous administration doesn't reliably translate to improved desire or arousal. Some observational data suggest indirect enhancements through partner dynamics, but controlled evidence is lacking. Bottom line: I don't currently recommend intranasal oxytocin for low libido treatment. The Elephant in the Room: Mind-Body Interventions Here's something that might surprise you: psychological and lifestyle interventions often show effect sizes comparable or superior  to supplements—and with arguably better evidence quality. Mindfulness-Based Therapy The research by Brotto and Basson (2014) found that group mindfulness therapy significantly improved sexual desire (the primary outcome), arousal, lubrication, satisfaction, and overall function. Increases in mindfulness skills and reductions in depressive symptoms predicted improvements in desire—suggesting mechanism. A 2025 RCT of the eSense online intervention found both CBT and mindfulness-based therapy arms showed large effect sizes versus waitlist: desire/arousal (d > 0.90), sexual distress (d < −0.62), and overall function (d = 1.20–1.23). Effects maintained at 6-month follow-up. These are impressive numbers that rival or exceed most supplement trials. Why This Matters for Integrative Practice Sexual desire is profoundly psychological. Chronic stress, relationship dynamics, past trauma, body image concerns, and negative sexual beliefs all contribute to low libido. Supplements can play a supportive role, but addressing these psychological factors often produces the most durable results. Consider cognitive behavioral sex therapy, sensate focus exercises, communication training, and addressing avoidance behaviors as part of comprehensive treatment. Putting It All Together: Evidence Summary Strongest Evidence (Meta-analytic Support) Tribulus terrestris: desire, arousal, orgasm, overall function Panax ginseng: desire, arousal Moderate Evidence (Multiple RCTs) Ashwagandha: arousal, lubrication, orgasm, satisfaction (especially with stress component) Saffron: arousal, lubrication, desire (especially for SSRI-induced dysfunction) Fenugreek: desire, hormonal effects Limited Evidence (Fewer/Smaller Trials) Maca: best for SSRI-induced dysfunction, postmenopausal women L-arginine combinations: variable by population Insufficient Evidence Ginkgo biloba: inconsistent results Intranasal oxytocin: no superiority over placebo Honest Assessment of Limitations I want to be transparent about what we don't know. Most trials have small sample sizes (30–100 participants), heterogeneous populations, and variable dosing regimens that make direct comparisons difficult. Placebo effects are substantial—sometimes 40% of placebo groups show improvement. Many studies have moderate-to-high risk of bias, and industry funding is common. Most trials run only 4–12 weeks, leaving long-term efficacy and safety uncertain. Does this mean supplements don't work? Not necessarily. It means we need to be humble about the strength of evidence and realistic with patients about what to expect. Clinical Recommendations for Practice Start with comprehensive assessment: Rule out medical conditions, medication effects, relationship factors, and psychological contributors. Consider functional medicine labs to identify underlying hormonal imbalances or nutritional deficiencies. Practice shared decision-making: Discuss the limited evidence quality, uncertainties, and set realistic expectations. Some patients will respond dramatically; others may see modest or no benefit. Consider combination approaches: Supplements work best as adjuncts to lifestyle modifications (stress reduction, exercise, sleep optimization) and psychological interventions (mindfulness, CBT, couples counseling). Choose quality products: Recommend standardized extracts from reputable manufacturers with third-party testing. Product quality varies enormously in the supplement industry. Allow adequate trial duration: Give supplements 8–12 weeks before assessing efficacy. Many patients expect faster results—manage these expectations upfront. Monitor for interactions: Be aware of potential herb-drug interactions, particularly with hormonal therapies, antidepressants, and blood thinners. Meet Dr. Yoon Hang Kim MD MPH At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com Key References 1. Sha'ari N, et al. Beneficial effects of natural products on female sexual dysfunction: A systematic review and meta-analysis. Phytomedicine . 2021;93:153760. PMID: 34638031 2. Martimbianco ALC, et al. Tribulus terrestris for female sexual dysfunction: A systematic review. Rev Bras Ginecol Obstet . 2020;42(7):427-435. PMID: 32736394 3. Dongre S, et al. Efficacy and safety of ashwagandha root extract in improving sexual function in women: A pilot study. Biomed Res Int . 2015;2015:284154. PMID: 26504795 4. Ajgaonkar A, et al. Efficacy and safety of ashwagandha root extract for improvement of sexual health in healthy women. Cureus . 2022;14(10):e30787. PMID: 36447681 5. Kashani L, et al. Crocus sativus (saffron) in the treatment of female sexual dysfunction: A three-center RCT. Avicenna J Phytomed . 2022;12(3):257-268. PMID: 36186931 6. Brotto LA, Basson R. Group mindfulness-based therapy significantly improves sexual desire in women. Behav Res Ther . 2014;57:43-54. PMID: 24814472 7. Cieri-Hutcherson NE, et al. Systematic review of L-arginine for hypoactive sexual desire disorder in women. Pharmacy (Basel) . 2021;9(2):71. 8. Oh KJ, et al. Effects of Korean red ginseng on sexual arousal in menopausal women. J Sex Med . 2010;7(4):1469-1477. 9. Rao A, et al. Influence of fenugreek seed extract on testosterone, estradiol and sexual function in healthy menstruating women. Phytother Res . 2015;29(8):1123-1130. 10. Dording CM, et al. A double-blind placebo-controlled trial of maca root for antidepressant-induced sexual dysfunction. Evid Based Complement Alternat Med . 2015;2015:949036. 11. Muin DA, et al. Effect of long-term intranasal oxytocin on sexual dysfunction: A randomized trial. Fertil Steril . 2015;104(3):612-619. 12. Ranjbar H, Ashrafizaveh A. Effects of saffron on sexual dysfunction among men and women: A systematic review and meta-analysis. Avicenna J Phytomed . 2019;9(5):419-427. Disclaimer: This review is for educational purposes only. Individual responses to supplements vary significantly. Consultation with a qualified healthcare professional is essential before initiating any supplement or therapy for sexual dysfunction. Supplements may interact with medications or underlying conditions.

Using LDN to Treat Neuropathy Edited by Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang “John” Kim is a fellowship-trained integrative and functional medicine physician with over 20 years of experience. He completed a residential fellowship in integrative medicine at the University of Arizona under Dr. Andrew Weil and is a 2024 Functional Medicine for All scholarship recipient from the Institute for Functional Medicine. After serving as Chief Wellness Officer at a rural community hospital in Illinois, Dr. Kim now provides virtual integrative and functional medicine care, expanding access to personalized, evidence-based treatment nationwide. His root-cause approach combines advanced functional lab testing with lifestyle medicine, nutrition, movement, mindfulness, and complementary therapies. Board-certified in preventive medicine, medical acupuncture, and integrative and holistic medicine, Dr. Kim has been a faculty member, consultant, and founder of an academic integrative health program. His clinical focus includes autoimmune disease, chronic pain, gastrointestinal disorders, integrative oncology, fibromyalgia, chronic fatigue syndrome, long COVID, and mold-related illness. He is the author of two books and more than 20 publications. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com Introduction Neuropathy—damage or dysfunction of peripheral nerves—represents a significant clinical challenge due to its prevalence and impact on quality of life. Conventional treatments, including anticonvulsants, antidepressants, and opioids, often provide incomplete relief and carry significant side effects. Low-dose naltrexone (LDN), an off-label use of naltrexone at doses typically ranging from 1 to 5 mg daily, has emerged as a promising option within integrative and functional medicine for various chronic pain conditions, including neuropathy. This article examines what LDN is, the pathophysiology of neuropathy with specific examples, the proposed mechanisms by which LDN may alleviate neuropathic symptoms, and evidence from clinical studies and trials. What is Low-Dose Naltrexone? Naltrexone is an opioid receptor antagonist approved for treating alcohol and opioid addiction at standard doses of 50 mg or higher. At these doses, it blocks opioid receptors to prevent euphoria and reduce cravings. Low-dose naltrexone refers to administration at significantly reduced doses—generally 1–5 mg per day, and sometimes even lower. This regimen is used off-label for its potential immunomodulatory and anti-inflammatory effects, particularly in chronic pain and inflammatory conditions. LDN is thought to work through transient opioid receptor blockade, leading to a compensatory increase in endogenous opioid production, and through non-opioid pathways involving glial cell modulation. Because commercial preparations are designed for higher doses, LDN is typically compounded into capsules or liquid formulations. Clinical observations suggest it's well-tolerated, with minimal side effects such as vivid dreams or mild gastrointestinal discomfort—making it an attractive alternative for patients intolerant to standard therapies. What is Neuropathy? Neuropathy, or peripheral neuropathy, encompasses a diverse group of disorders involving damage to peripheral nerves, resulting in sensory, motor, or autonomic dysfunction. Symptoms include pain, numbness, tingling, weakness, and autonomic disturbances. The condition arises from many causes: metabolic (diabetes), toxic (chemotherapy), infectious (herpes zoster), traumatic, autoimmune, nutritional deficiencies (particularly B vitamins), and sometimes idiopathic. Neuropathic pain is often described as burning, stabbing, or electric-shock-like and is mediated by central and peripheral sensitization. Glial cell activation in the central nervous system contributes to neuroinflammation, amplifying pain signals through proinflammatory cytokine release. This chronicity distinguishes neuropathic pain from nociceptive pain and makes it notoriously difficult to treat with conventional analgesics. Common Types of Neuropathy Neuropathies are classified by distribution (e.g., distal symmetric polyneuropathy) or underlying cause. Common examples include: Diabetic peripheral neuropathy  is the most prevalent form, affecting up to 50% of individuals with diabetes. It primarily involves sensory nerves in a stocking-glove distribution, leading to painful symptoms and increased risk of foot ulceration. Chemotherapy-induced peripheral neuropathy  results from neurotoxic agents used in cancer therapy, causing sensory loss, burning pain, numbness, and tingling that may persist long after treatment ends. Trigeminal neuralgia  is a cranial neuropathy involving the fifth cranial nerve, characterized by paroxysmal, lancinating facial pain triggered by innocuous stimuli like light touch or chewing. It often stems from vascular compression or demyelination and can be severely debilitating. Post-herpetic neuralgia  is a complication of herpes zoster (shingles), occurring in 10–20% of cases. Persistent pain follows rash resolution due to viral damage to sensory nerves. Other forms include small-fiber neuropathy (affecting autonomic and pain fibers) and complex regional pain syndrome (CRPS), which involves neuroinflammation and central sensitization. How LDN May Help Neuropathic Pain The analgesic effects of LDN in neuropathy are attributed primarily to its antagonism of Toll-like receptor 4 (TLR4) on microglial cells. Microglia, the resident immune cells of the central nervous system, become activated in response to nerve injury. Once activated, they release proinflammatory cytokines (TNF-α, IL-1β) that exacerbate central sensitization and worsen neuropathic pain. LDN inhibits TLR4 signaling, preventing excessive glial activation and attenuating this inflammatory cascade. This reduces neuroinflammation without fully blocking opioid receptors, allowing endogenous opioids to continue exerting their natural pain-modulating effects. Additionally, the transient opioid receptor blockade may upregulate endorphin production, enhancing the body's own pain control mechanisms. Preclinical evidence supports TLR4-mediated reversal of allodynia in neuropathic models, while clinical observations link LDN's benefits to reduced glial-driven inflammation in conditions like diabetic neuropathy and CRPS. Evidence from Studies and Clinical Trials Research on LDN for neuropathy is growing, though still dominated by small-scale studies, case series, and retrospective reviews. Key findings include: A randomized, double-blind, crossover trial involving 67 patients with painful diabetic neuropathy compared LDN (2–4 mg) to amitriptyline (10–50 mg). LDN demonstrated comparable pain reduction on visual analog scales with a superior safety profile and fewer adverse events. Retrospective cohort studies report significant pain relief in various neuropathic conditions. One analysis of chronic pain patients found LDN effective across multiple pain states, with greater benefits in neuropathic versus nociceptive pain—consistent with the TLR4 antagonism mechanism. Another case series noted improved outcomes in CRPS and diabetic neuropathy. For trigeminal neuralgia, preclinical rat models showed LDN reversing facial allodynia via TLR4 modulation. A retrospective case series in posttraumatic trigeminal neuropathic pain reported LDN as safe and effective. Post-herpetic neuralgia and related conditions (including neuropathic corneal pain) have shown symptom improvement in observational data, with LDN reducing pain and enhancing quality of life. Ongoing or completed trials registered on ClinicalTrials.gov include evaluations for painful diabetic neuropathy (NCT04678895) and CRPS (NCT06306157). The LDN Research Trust has compiled additional clinical and anecdotal reports of benefit in idiopathic, autonomic, and small-fiber neuropathies. Overall, evidence suggests LDN provides moderate pain relief in neuropathies—particularly those with inflammatory components—with low risk. However, larger randomized controlled trials are needed to establish efficacy more definitively. LDN Prescription and Administration LDN is most effectively prescribed by healthcare providers with training in integrative or functional medicine approaches. The process begins with a thorough assessment of the patient's medical history, current symptoms, and treatment goals to ensure LDN is appropriate. Most patients start at carefully titrated doses between 0.1 and 4.5 mg per day, typically administered at bedtime to minimize potential side effects like vivid dreams. Because standard commercial formulations aren't available at these low doses, LDN must be prepared by compounding pharmacies. Regular follow-up appointments are essential for assessing response and making dosage adjustments. This personalized approach—fundamental to integrative and functional medicine practice—helps optimize outcomes for patients managing chronic pain and autoimmune conditions. Comparison to Conventional Treatments Low-dose naltrexone represents a different approach compared to conventional therapies for chronic pain. While traditional treatments—opioids, anticonvulsants, and immunosuppressive medications—typically focus on symptom suppression and carry substantial side effect profiles, LDN works through immune modulation and inflammatory pathway regulation. This mechanism addresses underlying pathophysiology rather than merely masking symptoms. LDN's favorable safety profile, combined with its anti-inflammatory properties, makes it a compelling option for patients seeking alternatives to conventional pharmaceutical interventions. What distinguishes LDN in functional medicine practice is its ability to integrate into comprehensive treatment protocols that may also incorporate physical therapy, nutritional interventions, and other complementary modalities. Patient Experiences Clinical observations and published case series document that many patients with chronic pain and autoimmune conditions respond well to LDN as part of comprehensive care. Patients with diabetic neuropathy often report reduced pain intensity and improved sensory function. Those with multiple sclerosis have shown improvements in disability scores and reduced fatigue. Patients managing inflammatory bowel disease have demonstrated improvements in inflammatory markers and symptom severity. Responses to LDN vary considerably between individuals, and not all patients achieve optimal outcomes. However, clinical experience indicates that LDN protocols provide a reasonable therapeutic option for patients when conventional treatments have shown limited efficacy or tolerability. Future Directions Future studies are needed to determine optimal dosing strategies, ideal treatment durations, and which patient populations are most likely to benefit from LDN therapy. There's growing interest in exploring how LDN might work synergistically with other interventions—nutritional therapies, mind-body practices, and lifestyle modifications—to enhance outcomes. Research into the molecular mechanisms behind LDN's anti-inflammatory and immunomodulatory effects could inform development of new treatments for chronic pain and autoimmune diseases. Expanding clinical trials to include pediatric populations and patients with multiple complex conditions will also be important for understanding LDN's safety and efficacy across diverse groups. As the evidence base grows, low-dose naltrexone may become an increasingly valuable tool in managing chronic and complex conditions. Conclusion Low-dose naltrexone offers a non-opioid approach to managing neuropathy by targeting glial-mediated neuroinflammation through TLR4 inhibition. Preliminary evidence supports its use in diabetic neuropathy, trigeminal neuralgia, and post-herpetic neuralgia, with favorable tolerability. Its integration into functional and integrative medicine frameworks highlights its potential as an adjunctive therapy. While promising, LDN should be used under appropriate medical supervision, and more robust trial data will help clarify its role in neuropathy management. LDN Primer Request Check out the link below to request your free copy of the LDN Primer 2025! Meet Dr. Kim an expert in LDN, Integrative & Functional Medicine At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Chopra, P., & Cooper, M. S. (2013). Treatment of complex regional pain syndrome (CRPS) using low dose naltrexone (LDN). Journal of Neuroimmune Pharmacology, 8 (3), 470–476. https://doi.org/10.1007/s11481-013-9451-y Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). European Journal of Neuroscience, 28 (1), 20–29. https://doi.org/10.1111/j.1460-9568.2008.06321.x Kim, P. S., & Fishman, M. A. (2020). Low-dose naltrexone for chronic pain: Update and systemic review. Current Pain and Headache Reports, 24 (10), 64. https://doi.org/10.1007/s11916-020-00898-0 Martin, S. J., McAnally, H. B., Okediji, P., & Rogosnitzky, M. (2022). Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: A retrospective cohort study. Pain Management, 12 (6), 699–709. https://doi.org/10.2217/pmt-2021-0122 Patten, D. K., Schultz, B. G., & Berlau, D. J. (2018). The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn's disease, and other chronic pain disorders. Pharmacotherapy, 38 (3), 382–389. https://doi.org/10.1002/phar.2086 Soin, A., Soin, Y., Dann, T., Buenaventura, R., Ferguson, J., Atluri, S., & Sachdeva, H. (2021). Low-dose naltrexone use for patients with chronic regional pain syndrome: A systematic literature review. Pain Physician, 24 (4), E393–E406. Srinivasan, A., Dutta, P., Bansal, D., Chakrabarti, A., Bhansali, A. K., & Hota, D. (2021). Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. Journal of Diabetes, 13 (10), 770–778. https://doi.org/10.1111/1753-0407.13202 Younger, J., Mackey, S. (2009). Fibromyalgia symptoms are reduced by low-dose naltrexone: A pilot study. Pain Medicine, 10 (4), 663–672. https://doi.org/10.1111/j.1526-4637.2009.00613.x Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis & Rheumatism, 65 (2), 529–538. https://doi.org/10.1002/art.37734 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33 (4), 451–459. https://doi.org/10.1007/s10067-014-2517-2

Integrative Functional Medicine Approach to Enhancing Blood Flow Healthy blood flow is a foundation of systemic wellness. For practitioners of integrative medicine  and functional medicine , addressing poor circulation isn’t just about managing symptoms—it is about optimizing the body’s fundamental delivery system. When blood flow  is compromised, nutrient delivery and waste removal suffer, impacting everything from energy levels to tissue repair. Optimizing blood flow through integrative and functional medicine approaches offers significant health benefits, including improved cardiovascular function, enhanced oxygen delivery, and better overall wellness. This guide explores how these holistic disciplines approach vascular health, specifically examining the critical role of nitric oxide pathways and evidence-based supplementation. Maintaining optimal NO levels is essential for healthy circulation and cardiovascular health, as nitric oxide is a natural vasodilator that supports blood flow. Nitric oxide matters because it acts as a vital signaling molecule, promoting systemic wellness by improving circulation and oxygen delivery throughout the body. Introduction to Cardiovascular Health Cardiovascular pathophysiology represents the fundamental cornerstone of comprehensive systemic wellness optimization, exerting profound influence across multiple physiological parameters including metabolic energy production and overall longevity outcomes. Central to this complex cardiovascular system is nitric oxide, a critical endogenous signaling molecule with established vasodilatory properties that facilitates optimal hemodynamic function and maintains endothelial integrity. Evidence-based research demonstrates that nitric oxide biosynthesis is essential for maintaining normotensive blood pressure parameters, as this molecular mediator promotes vascular smooth muscle relaxation and arterial vasodilation, thereby optimizing systemic circulation and peripheral perfusion throughout the cardiovascular network. When nitric oxide production maintains appropriate physiological levels through established biochemical pathways, the incidence of cardiovascular disease significantly decreases, and comprehensive cardiovascular health outcomes demonstrate measurable improvement. Through evidence-based understanding and targeted support of nitric oxide-dependent signaling pathways, healthcare practitioners and patients can implement proactive, integrative interventions to optimize cardiac function and ensure sustained hemodynamic circulation for long-term cardiovascular wellness. Understanding Blood Flow Blood flow represents the fundamental circulatory mechanism upon which optimal physiological function depends, serving as the critical transport system that delivers essential oxygen and nutrients to cellular structures throughout the human body, much like the evidence-based complementary and alternative therapies that Dr. Kim incorporates into comprehensive medical treatments. This sophisticated vascular process relies extensively on the capacity of blood vessels to demonstrate dynamic expansion and contraction responses, a regulatory function predominantly governed by nitric oxide, which functions as a naturally occurring vasodilator with demonstrated efficacy in clinical applications. As a potent endogenous compound with vasodilatory properties, nitric oxide acts through established biochemical pathways to facilitate vessel dilation, thereby promoting enhanced blood flow dynamics and ensuring efficient oxygen delivery to target tissues and organ systems, particularly beneficial for patients with cardiovascular conditions, autoimmune disorders, and chronic conditions such as fibromyalgia and neuropathy. Maintaining optimal blood flow patterns proves essential for comprehensive cardiovascular health management, as this physiological process helps stabilize blood pressure parameters and significantly reduces the risk of developing cardiovascular disease and related complications commonly addressed through integrative medicine approaches. Supporting endogenous nitric oxide production through evidence-based interventions remains a cornerstone therapeutic strategy for preserving optimal blood vessel function and ensuring that the body's circulatory system operates at peak efficiency, utilizing the same holistic principles found in functional medicine practices that address root causes of disease through comprehensive assessment and targeted interventions. The Functional Medicine Approach to Blood Flow Unlike conventional models that may focus primarily on treating established vascular disease, a functional medicine perspective  seeks to identify the root causes of circulatory inefficiency before pathology sets in, emphasizing a holistic, root-cause approach to cardiovascular health. In this paradigm, blood flow  is viewed as a dynamic marker of overall vitality. Functional medicine practitioners often assess vascular health by looking at endothelial function—the health of the inner lining of blood vessels. When the endothelium is damaged or sluggish, it fails to produce adequate signaling molecules required for vasodilation (the widening of blood vessels). Optimizing circulation involves a comprehensive strategy: Nutrient Status:  Ensuring the body has the raw materials for vascular repair. Inflammation Control:  Reducing systemic inflammation that damages vessel walls. Lifestyle Factors:  Incorporating movement and stress reduction to support hemodynamic balance. Functional medicine solutions address these root causes by personalizing interventions that restore natural balance, focusing on diet, lifestyle, and correcting systemic imbalances for optimal circulatory health. Integrative Medicine and the Nitric Oxide Pathway A core component of vascular health in integrative medicine  is the management of nitric oxide (NO). Nitric oxide plays a crucial role in cardiovascular health and circulation, acting as a biological signaling molecule essential for vasodilation. Note that while often confused in casual conversation with nitrous oxide  (an anesthetic gas), we are specifically focusing on nitric oxide . However, understanding the distinction is vital for patients. Nitrous oxide  is used in dental sedation and pain management, whereas nitric oxide is produced naturally by the body to relax vascular smooth muscles. Nitric oxide widens blood vessels, enhancing blood flow and oxygen delivery, which is crucial for overall cardiovascular health. Enhancing the bioavailability of nitric oxide is a primary goal when attempting to improve blood flow  naturally. Mechanisms of Action The endothelium produces nitric oxide to signal blood vessels to relax. This reduces vascular resistance and improves circulation to extremities and vital organs. Integrative medicine  protocols often utilize specific precursors to fuel this pathway: L-Arginine and L-Citrulline:  These amino acids serve as direct substrates for NO synthesis. L-arginine is an amino acid that acts as a precursor for nitric oxide, while L-citrulline is a non-essential amino acid that is naturally synthesized in the body and can be converted into L-arginine. Dietary Nitrates:  Compounds found in foods like beetroot are converted via the nitrate-nitrite-NO pathway, offering an alternative route for vasodilation that is particularly useful if the endothelial pathway is compromised. Nitric oxide synthase is the key enzyme responsible for converting these amino acids into nitric oxide, playing a central role in regulating blood flow and vascular health. Key Supplements for Circulatory Support When selecting interventions, evidence supports several natural compounds that align with functional medicine  principles. Dietary supplements are commonly used in functional medicine to support circulatory health. These supplements aim to restore physiological balance and enhance endothelial performance, with many focusing on the benefits of nitric oxide for cardiovascular and circulatory health, such as improved blood flow, heart function, and overall wellness. 1. Beetroot Extract and Nitrates Beetroot is a powerhouse for vascular health and is considered one of the most effective nitric oxide supplements. Rich in inorganic nitrates, it bypasses the enzymatic pathways that are often dysfunctional in aging adults. Mechanism:  Converts to nitric oxide in the mouth and stomach. Evidence:  Systematic reviews suggest consistent improvements in blood pressure and endothelial function, and show that beetroot extract reduces high blood pressure through its effects on nitric oxide production. Clinical Note:  Effective doses typically provide at least 370 mg of nitrates. 2. L-Citrulline vs. L-Arginine While L-arginine is the direct precursor, L-citrulline is often preferred in integrative medicine  protocols due to better absorption. L-citrulline is converted into L-arginine in the kidneys, sustaining plasma levels of arginine longer than direct arginine supplementation. Both L-citrulline and L-arginine support cardiovascular health by promoting vasodilation, which enhances blood flow and helps reduce strain on the heart. Dosing:  Studies suggest 5.6–8 g of L-citrulline for optimal vasodilation. These supplements also help maintain healthy blood pressure levels within the normal range. 3. Omega-3 Fatty Acids Beyond their anti-inflammatory properties, Omega-3s—commonly found in fish oil, a primary source of EPA and DHA—support the structural integrity of blood vessels. In addition to reducing systemic inflammation, the antioxidant properties of omega-3 fatty acids help prevent the endothelial damage that restricts blood flow . 4. Aged Garlic Extract Garlic compounds, specifically allicin-rich preparations, have been shown to promote vasodilation and improve arterial stiffness, making them a staple in cardiovascular support strategies. Aged garlic extract, in particular, supports vascular function by enhancing the health and flexibility of blood vessels. Additionally, aged garlic extract contributes to metabolic health, supporting balanced blood sugar and overall wellness. Lifestyle Factors Affecting Health Evidence-based lifestyle interventions demonstrate profound therapeutic efficacy in optimizing cardiovascular health and enhancing endothelial nitric oxide synthesis through comprehensive integrative approaches. A scientifically-formulated nutritional protocol—particularly one incorporating antioxidant-rich phytonutrient sources including cruciferous vegetables, polyphenol-abundant fruits, and complex carbohydrate whole grain substrates—provides essential cofactors and precursors for nitric oxide biosynthesis while supporting optimal endothelial function and hemodynamic parameters. Structured physical activity protocols not only strengthen myocardial contractility but also demonstrate clinically significant reductions in systolic and diastolic blood pressure measurements while upregulating nitric oxide bioavailability through enhanced endothelial nitric oxide synthase activity. Implementation of evidence-based mind-body therapeutic modalities, including diaphragmatic breathing techniques and mindfulness-based stress reduction protocols, can significantly attenuate oxidative stress markers and support optimal cardiovascular function through parasympathetic nervous system activation. Through systematic implementation of these evidence-based integrative lifestyle modifications, patients can achieve measurable improvements in nitric oxide production, enhance endothelial-dependent vasodilation, and demonstrate clinically significant risk reduction in cardiovascular disease endpoints. The Effects of Chronic Stress Chronic stress represents a clinically significant yet frequently underrecognized pathophysiological factor in cardiovascular health management, according to evidence-based integrative medicine approaches. The persistent activation of stress-response mechanisms triggers the body's sympathetic nervous system, resulting in vasoconstriction and elevated blood pressure parameters through well-documented neurohormonal pathways. Over time, these sustained physiological responses lead to endothelial dysfunction, characterized by decreased nitric oxide bioavailability and compromised vascular endothelium function, as demonstrated through comprehensive functional medicine assessments. The clinical manifestation includes substantially increased cardiovascular disease risk profiles and compromised circulatory system integrity across multiple patient populations. Evidence-based stress management interventions, including mind-body techniques such as deep breathing protocols, meditation practices, and therapeutic yoga modalities—approaches widely incorporated in integrative and holistic medicine—have been clinically validated to restore optimal nitric oxide production, support healthy vascular function, and provide comprehensive cardiovascular protection. Through the implementation of integrative approaches to chronic stress management, patients can achieve significant therapeutic outcomes in maintaining healthy blood pressure parameters and substantially reducing cardiovascular disease risk factors, representing a fundamental component of preventive and functional medicine practice. Safety and Clinical Considerations In the spirit of integrative medicine , safety is paramount. Supplements are powerful tools, but they must be used methodically. Individuals with kidney disease should consult a healthcare provider before using supplements that affect blood flow. People with high blood pressure should also exercise caution when considering these supplements. Interaction Risks Patients taking anti-hypertensives or blood thinners must exercise caution. Enhancing blood flow  naturally can potentiate the effects of these medications, leading to hypotension (low blood pressure) or increased bleeding risk. Some supplements used to enhance blood flow are also commonly used to address erectile dysfunction and support sexual function. Quality Assurance The supplement industry is not strictly regulated. Functional medicine  practitioners emphasize using "pharmaceutical grade" or third-party tested products to ensure purity and potency. Professional Guidance Before starting any regimen, consultation with a healthcare provider is essential. This ensures that the chosen therapy aligns with the patient's unique physiological profile and current medication list. Conclusion Optimizing blood flow  through integrative medicine  and functional medicine  offers a proactive approach to cardiovascular health. Preventive medicine plays a crucial role in maintaining cardiovascular and overall health by emphasizing early intervention and lifestyle modifications. By focusing on the nitric oxide pathways and utilizing high-quality, evidence-based supplements like beetroot extract and L-citrulline, patients can support their circulatory systems naturally. Optimizing blood flow and nitric oxide production also supports immune function and gut health, contributing to broader systemic wellness. As with all medical interventions, a personalized, methodical approach yields the best results. Always consult with a qualified physician to integrate these strategies safely into your healthcare routine. About Dr. Kim Dr. Yoon Hang "John" Kim, residential fellowship trained in integrative medicine at University of Arizona and a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com https://youtu.be/qNxc1mc9yA8?si=RUUs8EJZShr9P7_D Meet Dr. Kim Integrative & Functional Medicine and LDN Expert References Bahra, M., & Kapil, V. (2022). Dietary supplements for improving nitric-oxide synthesis. Medicine , 2(1), 1–12. Lidder, S., & Webb, A. J. (2013). Vascular effects of dietary nitrate via the nitrate-nitrite-nitric oxide pathway. British Journal of Clinical Pharmacology , 75(3), 677–696. Mahdi, A., & Collins, P. (2023). Dietary arginine and citrulline supplements for cardiovascular health and athletic performance. Nutrients , 15(5), 1268. Mayo Clinic. (2024). L-arginine: Does it lower blood pressure? Verywell Health. (2025). Dietary supplements for blood flow.

Edited by Yoon Hang Kim, MD, MPH Dr. Yoon Hang "John" Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies, including meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has contributed as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. Dr. Kim specializes in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID, and toxic mold illness. He has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiries:   www.yoonhangkim.com Clinical Inquiries:   www.directintegrativecare.com Boron and Prostate Cancer: An Introduction - Boron Prostate Health Integrative Functional Medicine Boron is a trace mineral found in fruits, vegetables, nuts, and legumes. While not officially classified as essential for humans, some researchers consider it vital due to its roles in cellular function and metabolism. Boron has been studied for hormone regulation, bone health, and inflammation modulation. Recent research has explored its potential impact on prostate health, particularly prostate cancer risk. Epidemiological, in vitro, and animal studies suggest possible protective effects, although human evidence remains mixed. Many epidemiological studies account for confounding factors such as alcohol consumption, body mass index, and dietary caloric intake. Boron-containing compounds are increasingly investigated as preventive and therapeutic agents in cancer research. This review summarizes the current evidence from epidemiology, preclinical studies, clinical observations, and expert opinion. Epidemiological Evidence of Prostate Cancer Risk Studies Supporting Protective Effects Several observational studies have examined dietary boron and prostate cancer risk. Data from the Third National Health and Nutrition Examination Survey (NHANES III) showed that higher dietary boron intake was associated with a lower risk of prostate cancer in a dose-dependent manner. Men in the highest quartile of boron intake had an adjusted odds ratio of 0.46 (95% CI: 0.21–0.98) compared to the lowest quartile (Cui et al., 2004). Risk was 52% lower in men consuming >1.8 mg/day of boron compared to ≤0.9 mg/day. No correlation was observed when intake was <1.17 mg/day (Pizzorno, 2015). An ecological study in Texas reported that higher groundwater boron levels correlated with lower prostate cancer incidence and mortality (R = 0.6 for both), while selenium showed no correlation (R = 0.1–0.2) (Barranco et al., 2007). Conflicting Evidence However, the VITamins And Lifestyle (VITAL) cohort study of 35,244 men found no association between dietary or total boron intake and prostate cancer risk (hazard ratio 1.17; 95% CI: 0.85–1.61) (Gonzalez et al., 2007). Foods high in boron were not associated with decreased risk. These discrepancies may result from differences in study design, sample size, dietary assessment, and population characteristics. Variations in controlling for confounders like alcohol intake, BMI, and total caloric intake may also contribute. Preclinical Evidence In Vitro Studies Boric acid, the main plasma form of boron, inhibits proliferation of prostate cancer cell lines (DU-145, LNCaP) in a dose-dependent manner, while requiring higher concentrations to affect non-tumor cells (Barranco & Eckhert, 2004). Recent studies (2025) on boron derivatives such as sodium pentaborate pentahydrate (SPP) and sodium perborate tetrahydrate (SPT) show selective cytotoxicity toward prostate cancer cells, targeting mitochondrial function and RNA metabolism, with effects varying by androgen status (Demirdogen et al., 2025). Proposed mechanisms include: Inhibition of prostate-specific antigen (PSA) activity via boronic acid Reduction in intracellular calcium signaling Induction of stress granule formation Modulation of inflammatory pathways Downregulation of IGF-1 signaling Impairment of lipid metabolism through mitochondrial regulators (ACSL3, PYCR1, PYCR2) Induction of apoptosis in prostate cancer cells Animal Studies Dietary boron supplementation in mice reduced LNCaP tumor growth by 25–38% and decreased serum PSA by 86–89% (Gallardo-Williams et al., 2004). Hollow boron nitride spheres suppressed tumor growth and enhanced paclitaxel efficacy in mouse models (Li et al., 2017). Hexagonal boron nitride nanoparticles promoted apoptosis and reduced metastatic potential (Emanet et al., 2019). Mechanisms of Boron’s Effects Boron affects prostate cancer cells via multiple pathways: Proliferation inhibition:  Reduces tumor cell growth in both androgen-sensitive and independent cell lines. Apoptosis induction:  Triggers programmed cell death selectively in malignant cells. Migration reduction:  Disrupts cellular architecture, limiting metastatic spread. Hormonal modulation:  Influences testosterone metabolism, potentially complementing androgen deprivation therapy. Bone health support:  May prevent metastatic growth in bone tissue. Research relies on rigorous in vitro, animal, and dietary studies to clarify boron’s role in prostate cancer risk and progression. Clinical Trial Evidence No registered human clinical trials have specifically evaluated boron for prostate cancer prevention or treatment (NIH ODS, 2024). Related human studies include: Inflammation:  10 mg/day boron supplementation for 1 week reduced TNF-α by 20%, hs-CRP by ~50%, and IL-6 (Naghii et al., 2011). Prostate size:  Men consuming ~6 mg/day had smaller prostates than those consuming 0.64–0.88 mg/day, with no significant PSA differences (NIH ODS, 2024). Hormones:  Boron supplementation increased free testosterone in men and supported bone health in postmenopausal women (Naghii et al., 2011). Boron Neutron Capture Therapy (BNCT):  Preclinical prostate studies show promise; PSMA-targeted boron agents are under development (Takahara et al., 2015; Wilson et al., 2019). Expert Opinion and Clinical Perspectives Lara Pizzorno (2015) recommends considering 3 mg/day boron supplementation for individuals with low fruit and vegetable intake or at risk of osteopenia, osteoporosis, osteoarthritis, or hormone-sensitive cancers. Some integrative practitioners report PSA reduction and prostate size improvement with higher doses (3–20 mg/day), though systematic documentation is lacking. Patient Experience No formal patient-reported outcome studies exist. Anecdotal reports suggest subjective improvements in urinary symptoms and PSA levels, but these are not systematically documented. Dietary Boron Intake: Sources and Recommendations Boron is obtained primarily from plant-based foods. Typical intake ranges from 1–3 mg/day; the tolerable upper intake is 20 mg/day. Key sources: Fruits:  Apples, pears, grapes, avocados, prunes, raisins Vegetables:  Broccoli, carrots, leafy greens Nuts/Legumes:  Almonds, peanuts, hazelnuts, lentils Other:  Wine, coffee, milk Supplementation may be considered for intakes <3 mg/day, especially in individuals with low fruit and vegetable consumption (Pizzorno, 2015). Summary of Evidence Evidence Type Availability Quality Key Findings Epidemiological Mixed Moderate Conflicting results In Vitro Strong Good Dose-dependent inhibition of cancer cells Animal Strong Good 25–38% tumor reduction, 86–89% PSA reduction Human RCTs None N/A Evidence gap Expert Opinion Cautiously Favorable Low-Moderate Supports 3 mg/day for at-risk individuals Patient Experience Anecdotal Very Low No systematic data Conclusions - Boron Prostate Health Integrative Functional Medicine Preclinical studies suggest boron may inhibit prostate cancer growth and reduce tumor progression. Epidemiological data indicate higher boron exposure may correlate with lower prostate cancer risk. The major limitation is the absence of human clinical trials specifically targeting prostate cancer, highlighting a critical evidence gap. Boron appears safe up to 20 mg/day, but supplementation for prostate health should be approached cautiously. Boron Prostate Health Integrative Functional Medicine - At this time, I would recommend taking Boron up to 3 mg/day. Clinical considerations: 3 mg/day appears safe with potential anti-inflammatory benefits Upper limit of 20 mg/day is low-risk Dietary intake from fruits and vegetables is preferred Human clinical trials are needed to establish efficacy At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality.  Yoon Hang Kim MD Integrative & Functional Medicine Physician Virtual Practice Serving IA, IL, MO, FL, GA, and TX www.directintegrativecare.com References Barranco, W. T., & Eckhert, C. D. (2004). Boric acid inhibits human prostate cancer cell proliferation. Cancer Letters , 216(1), 21–29. https://doi.org/10.1016/j.canlet.2004.06.001 Barranco, W. T., Hudak, P. F., & Eckhert, C. D. (2007). Evaluation of ecological and in vitro effects of boron on prostate cancer risk (United States). Cancer Causes & Control , 18(1), 71–77. https://doi.org/10.1007/s10552-006-0077-8 Cui, Y., et al. (2004). Dietary boron intake and prostate cancer risk. Oncology Reports , 11(4), 887–892. https://doi.org/10.3892/or.11.4.887 Demirdogen, R. E., et al. (2025). Proteomic insights into the anti-cancer mechanisms of boron-based compounds in prostate cancer. Journal of Proteomics . [Epub ahead of print] Emanet, M., et al. (2019). Hexagonal Boron Nitride Nanoparticles for Prostate Cancer Treatment. ACS Applied Nano Materials , 2(12), 7493–7504. Gallardo-Williams, M. T., et al. (2004). Boron supplementation inhibits the growth and local expression of IGF-1 in human prostate adenocarcinoma (LNCaP) tumors in nude mice. Toxicologic Pathology , 32(1), 73–78. https://doi.org/10.1080/01926230490260899 Gonzalez, A., et al. (2007). Boron intake and prostate cancer risk. Cancer Causes & Control , 18(10), 1131–1140. https://doi.org/10.1007/s10552-007-9052-2 Li, X., et al. (2017). Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment. Nature Communications , 8, 13936. https://doi.org/10.1038/ncomms13936 Naghii, M. R., et al. (2011). Comparative effects of daily and weekly boron supplementation on plasma steroid hormones and proinflammatory cytokines. Journal of Trace Elements in Medicine and Biology , 25(1), 54–58. Pizzorno, L. (2015). Nothing boring about boron. Integrative Medicine: A Clinician's Journal , 14(4), 35–48. Scorei, R. I., & Popa, R. (2013). Sugar-borate esters—potential chemical agents in prostate cancer chemoprevention. Anti-Cancer Agents in Medicinal Chemistry , 13(6), 901–909. Takahara, K., et al. (2015). The anti-proliferative effect of boron neutron capture therapy in a prostate cancer xenograft model. PLoS ONE , 10(9), e0136981. https://doi.org/10.1371/journal.pone.0136981 U.S. Department of Health and Human Services, NIH Office of Dietary Supplements. (2024). Boron: Fact sheet for health professionals. https://ods.od.nih.gov/factsheets/Boron-HealthProfessional/ Wilson, J. J., et al. (2019). Synthesis and initial biological evaluation of boron-containing PSMA ligands for treatment of prostate cancer using BNCT. Molecular Pharmaceutics , 16(9), 3831–3841. https://doi.org/10.1021/acs.molpharmaceut.9b00464

Edited By Yoon Hang Kim MD MPH About Dr. Kim Dr. Yoon Hang "John" Kim, a recipient of the 2024 Functional Medicine for All scholarship from the Institute for Functional Medicine, brings over 20 years of experience in integrative and functional medicine to his telemedicine practice. After serving as chief wellness officer at a community hospital in Carthage, IL, where he provided care to rural and underserved populations, Dr. Kim now offers virtual integrative and functional medicine services, making personalized, evidence-based care accessible to patients regardless of location. His approach combines functional medicine lab testing with complementary therapies such as meditation, yoga, tai chi, and lifestyle interventions using food and physical activity as medicine, addressing the root causes of disease. Dr. Kim earned his medical degree from the Medical College of Wisconsin, completed a master’s in public health at San Diego State University, and trained with Dr. Andrew Weil during his residential fellowship at the University of Arizona. Certified by the American Board of Preventive Medicine, the American Board of Medical Acupuncture, and the American Board of Integrative and Holistic Medicine, he has also contributed to the field as a faculty member, consultant, and founder of the Integrative Health Studies Certificate program at the University of West Georgia. With clinical interests in autoimmune conditions, chronic pain, integrative oncology, and gastrointestinal disorders, Dr. Kim specializes in treating complex conditions such as fibromyalgia, chronic fatigue syndrome, long COVID symptoms, and toxic mold illness, and has authored two books and over 20 articles while helping establish integrative medicine practices across various institutions. Professional Inquiry: www.yoonhangkim.com Clinical Inquiry: www.directintegrativecare.com Low-Dose Naltrexone for Weight Loss: Mechanisms, Evidence, and Comparison with Naltrexone/Bupropion Combination Therapy Obesity remains a significant public health challenge, contributing to comorbidities such as type 2 diabetes, cardiovascular disease, and metabolic syndrome. Pharmacological interventions, when combined with lifestyle modifications, offer adjunctive support for weight management. Among emerging options, low-dose naltrexone (LDN) , typically dosed at 1–5 mg daily, has garnered interest for its potential off-label use in weight loss due to its immunomodulatory and anti-inflammatory effects. Additionally, the fixed-dose combination of standard-dose naltrexone (32 mg) and bupropion (360 mg), marketed as Contrave, is an FDA-approved therapy specifically for chronic weight management. This article reviews the mechanisms and evidence for LDN in weight loss and examines the established naltrexone/bupropion combination. Low Dose Naltrexone Weight Loss: Mechanisms of Action - LDN Weight Loss Integrative Functional Medicine San Antonio TX Naltrexone is an opioid receptor antagonist primarily approved at higher doses (50 mg) for opioid and alcohol dependence. At high doses, naltrexone blocks opioid receptors, preventing users from experiencing the euphoric feelings associated with opioids and alcohol. At low doses, LDN is hypothesized to transiently block opioid receptors, leading to a rebound increase in endogenous endorphins, which play a role in mood regulation and pain relief, and modulation of glial cell activity. LDN work includes reducing inflammation and supporting mood regulation. This may reduce systemic inflammation, improve insulin sensitivity, regulate appetite, and enhance sleep quality—all factors implicated in obesity. Low dose naltrexone may support appetite control and reduce food cravings by modulating the opioid system, which is involved in addictive eating behaviors. Proposed pathways include decreased insulin resistance, reduced inflammatory cytokines, and indirect effects on growth hormone secretion, potentially preserving lean muscle mass while promoting fat loss. LDN may also help address leptin resistance, which can impair hunger signals and contribute to overeating. How low dose naltrexone is thought to work for weight loss involves its impact on the opioid system and endorphin release, influencing appetite and metabolic pathways. In contrast, the naltrexone and bupropion combination targets central nervous system pathways regulating energy balance and is FDA approved for weight loss. Bupropion, a dopamine and norepinephrine reuptake inhibitor, stimulates pro-opiomelanocortin (POMC) neurons in the hypothalamus, promoting satiety and energy expenditure. Naltrexone at standard doses blocks autoinhibitory feedback on POMC neurons, enhancing these effects synergistically. This combination primarily suppresses appetite and reduces food reward, distinct from LDN’s broader anti-inflammatory focus. Weight loss naltrexone (in combination with bupropion) is supported by clinical evidence. Evidence for Low-Dose Naltrexone in Weight Loss Evidence supporting LDN for weight loss is largely preliminary and derived from observational data, small trials, and mechanistic studies rather than large randomized controlled trials (RCTs). Systematic reviews indicate limited high-quality data specific to obesity, with most research focusing on LDN’s role in autoimmune or inflammatory conditions. Potential benefits include improved insulin regulation and reduced cravings, particularly in conditions like polycystic ovary syndrome or hypothyroidism-associated weight gain, and LDN may also help regulate blood sugar. LDN may help manage binge eating and reduce cravings for certain foods, which can support healthier eating behaviors. While some individuals report weight loss, successful weight loss with LDN still requires maintaining a caloric deficit and consuming fewer calories than expended. It is important to address eating disorders and ensure medical supervision when taking naltrexone for weight loss, as misuse or unsupervised use can be harmful. However, no large-scale RCTs have confirmed significant, sustained weight loss with LDN monotherapy. Clinical use remains off-label, and effects appear modest, often requiring combination with diet and exercise. In clinical practice, taking naltrexone may help some individuals lose weight by reducing cravings and supporting healthier eating patterns. LDN Weight Loss Integrative Functional Medicine San Antonio TX Review of Naltrexone/Bupropion Combination (Contrave) The naltrexone/bupropion extended-release formulation combines two medications that work synergistically: naltrexone helps reduce cravings, while bupropion boosts energy and suppresses appetite. Robust evidence from phase III RCTs, including the COR-I, COR-II, COR-BMOD, and COR-Diabetes trials, involving over 4,500 participants, supports its efficacy. These 56-week studies demonstrated placebo-subtracted weight loss of approximately 4.7% (range 3.2–5.2%), with 26–33% more patients achieving ≥5% weight loss compared to placebo when combined with lifestyle interventions. In intensive behavior modification settings, weight loss exceeded 9%. Improvements in cardiometabolic parameters, such as waist circumference, triglycerides, and insulin sensitivity, were also observed. Long-term data suggest sustained benefits, though nausea is a common adverse effect leading to discontinuation in some patients. It is important to use this combination only under medical supervision to manage potential risks and side effects. Compared to LDN, the standard-dose combination offers more predictable and clinically meaningful weight loss, supported by regulatory approval and larger evidence bases. Naltrexone is also used in the management of substance use disorder, highlighting its established safety profile in clinical use. No direct head-to-head trials exist between LDN and Contrave, but the latter’s targeted central appetite regulation appears superior for primary obesity management. Potential Side Effects of LDN Low dose naltrexone (LDN) represents an evidence-based therapeutic intervention typically prescribed at significantly reduced dosages compared to those utilized in opioid or alcohol dependency treatment protocols, and demonstrates excellent tolerability profiles across diverse patient populations. However, as with any pharmaceutical intervention in integrative medicine practice, comprehensive awareness of potential adverse reactions and implementation under qualified healthcare supervision remains paramount to optimal patient outcomes. The majority of patients receiving low dose naltrexone therapy for weight management, metabolic optimization, or associated endocrine disorders experience only transient, mild adverse effects that align with established clinical research findings. These may encompass cephalgia, gastrointestinal disturbances such as nausea, enhanced dream activity, or minor sleep pattern modifications. Such symptoms characteristically resolve within several weeks as the patient's physiological systems achieve therapeutic adaptation to the prescribed naltrexone dosage. Numerous patients report significant improvements in sleep architecture over time, which provides additional therapeutic support for weight management protocols and comprehensive wellness optimization. In rare clinical instances, more significant adverse reactions may manifest. These include severe dermatological responses, allergic hypersensitivity reactions, chest discomfort, or respiratory compromise. Should any severe symptomatology or dermatological manifestations occur, immediate medical evaluation becomes critically important for patient safety. While such reactions remain infrequently documented in clinical literature, maintaining vigilant patient monitoring ensures optimal safety protocols throughout the treatment continuum. LDN demonstrates potential pharmaceutical interactions, particularly with opioid analgesics, and may present contraindications for individuals with specific medical conditions including hepatic or renal dysfunction. Comprehensive disclosure of complete medical history and concurrent medications or nutraceutical supplements to your healthcare provider before initiating low dose naltrexone therapy remains essential for safe clinical practice. This becomes particularly crucial when utilizing LDN for managing severe manifestations of autoimmune pathologies, chronic pain syndromes, or irritable bowel syndrome, as these complex conditions require sophisticated clinical monitoring and integrative treatment approaches. To optimize therapeutic outcomes while minimizing adverse effects, adherence to evidence-based treatment protocols established by qualified healthcare practitioners becomes fundamental. LDN therapy typically commences at conservative dosages, generally ranging from 1.5mg to 4.5mg daily, often administered at bedtime to support circadian rhythm regulation and sleep quality enhancement. Integration of LDN with caloric restriction protocols, structured physical activity programs, and comprehensive lifestyle modifications can amplify therapeutic benefits for weight management and metabolic syndrome, while simultaneously supporting immune system function and hormonal equilibrium. Beyond its established role in weight management protocols, LDN has demonstrated significant therapeutic promise for enhancing insulin sensitivity, reducing systemic inflammatory markers, and supporting endocrine balance optimization. Current research investigations continue exploring its therapeutic potential for managing severe symptomatology in conditions such as multiple sclerosis and other autoimmune pathologies, representing exciting developments in integrative medicine applications. Ultimately, while low dose naltrexone provides a promising evidence-based therapeutic option for individuals managing excess adiposity, metabolic syndrome, or chronic pain conditions, it does not replace comprehensive lifestyle interventions fundamental to integrative medicine practice. A holistic treatment approach incorporating nutritional modifications, regular physical activity protocols, and stress management techniques remains essential for achieving sustained long-term therapeutic success. Through collaborative partnership with qualified healthcare providers and dedicated adherence to established treatment protocols, patients can maximize LDN's therapeutic benefits while maintaining optimal safety profiles. Should any severe symptomatology develop or concerns regarding adverse effects arise, prompt communication with your healthcare provider ensures appropriate clinical guidance and intervention. Patient Perspectives and Experiences Many patients struggling with weight management have turned to low dose naltrexone as part of a comprehensive approach, particularly when conventional methods haven't produced lasting results. People dealing with obesity alongside conditions like insulin resistance, PCOS, hypothyroidism, or chronic inflammation frequently report reduced cravings, improved appetite control, better sleep, and enhanced energy levels that support their weight loss efforts. Clinical observations align with these reports. Patients often describe feeling less driven by food cravings and finding it easier to maintain dietary changes. Some note improvements in mood and reduced emotional eating patterns—factors that often undermine weight loss attempts. Beyond the number on the scale, practitioners have documented improvements in metabolic markers and overall well-being. For many patients, LDN has helped address the inflammatory and hormonal imbalances that can make weight loss particularly challenging. Patients sometimes describe LDN as a helpful tool that makes sustainable lifestyle changes feel more achievable. The mechanism appears to involve immune modulation, improved insulin sensitivity, and normalization of appetite signaling. That said, responses to LDN vary considerably. While many patients benefit, some don't achieve meaningful results. Weight loss with LDN still requires a caloric deficit and commitment to dietary and lifestyle changes—it supports rather than replaces these fundamentals. Consultation with a knowledgeable provider is essential to determine appropriateness and monitor progress. As research continues, LDN's role in metabolic health and weight management will become better defined—offering another option for patients seeking integrative approaches to sustainable weight loss. Resources Facebook LDN Support Group: https://www.facebook.com/groups/2927649837416056 LDN Support Group Website: www.ldnsupportgroup.com Dr. Kim's LDN Blog: https://www.directintegrativecare.com/integrative-medicine-blog Dr. Kim's LDN YouTube Channel: https://www.youtube.com/@YoonHangKimMD Request your free copy of the LDN Primer 2025: https://www.ldnsupportgroup.org/projects-6Conclusion Low-dose naltrexone shows theoretical promise for weight loss through anti-inflammatory and metabolic pathways, yet evidence remains limited and primarily anecdotal or indirect. In contrast, the naltrexone/bupropion combination (Contrave) is well-substantiated for producing significant, sustained weight loss as an adjunct to lifestyle changes. Clinicians should consider patient-specific factors, including comorbidities and tolerance, when evaluating these options. Further RCTs are needed to clarify LDN's role in obesity treatment. Meet Dr. Yoon Hang Kim MD MPH Integrative & Functional Medicine and LDN Therapy Expert At Direct Integrative Care, Dr. Kim is dedicated to guiding you on your path to wellness through a deeply personalized and supportive approach. We focus on integrative medicine, looking beyond symptoms to uncover the root causes of chronic conditions and develop a treatment plan tailored specifically to your unique health journey. By combining compassionate care with innovative therapies, our goal is to empower you with the knowledge and tools needed to achieve lasting health. We invite you to explore our website to learn more about how our patient-centered practice can help you find balance and vitality. Yoon Hang Kim, MD Direct Integrative Care www.directintegrativecare.com Virtual Integrative Functional Tele-Medicine in IA, IL, MO, GA, FL, and TX Text and Phone 210.981.6106 Toll Free 855.462.0188 References Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet , 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 Kulak-Bejda, A., Bejda, G., & Waszkiewicz, N. (2021). Safety and efficacy of naltrexone for weight loss in adult patients – a systematic review. Archives of Medical Science , 17(4), 920–929. https://doi.org/10.5114/aoms.2020.100183 Wadden, T. A., Foreyt, J. P., Foster, G. D., Hill, J. O., Klein, S., O'Neil, P. M., Perri, M. G., Pi-Sunyer, F. X., Rock, C. L., Erickson, J. S., Maier, H. N., Kim, D. D., & Dunayevich, E. (2011). Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial. Obesity , 19(1), 110–120. https://doi.org/10.1038/oby.2010.147 Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology , 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2